{"gene":"GTF2I","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1993,"finding":"TFII-I defines an alternative transcription initiation pathway through direct binding to the initiator (Inr) element, forming preinitiation complexes distinct from those formed with TFIIA; TBP binds cooperatively with TFII-I at Inr-containing TATA-less promoters, enabling a TFIID-dependent pathway at TATA-less promoters.","method":"In vitro transcription reconstitution, preinitiation complex assembly assays, sequential factor addition","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro transcription pathway with defined factors, published in two companion papers from Roeder lab","pmids":["8377828"],"is_preprint":false},{"year":1993,"finding":"Myc interacts physically with TFII-I and inhibits TFII-I-dependent transcription initiation selectively, correlating with prevention of TBP–TFII-I–promoter complex formation; this inhibition is specific to the TFII-I-dependent (not TFIIA-dependent) initiation pathway.","method":"In vitro transcription assay, protein–protein interaction (co-immunoprecipitation/pulldown), preinitiation complex formation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with functional read-out and mechanistic dissection of pathway specificity","pmids":["8377829"],"is_preprint":false},{"year":1997,"finding":"TFII-I encodes a 120 kDa polypeptide containing six directly repeated ~90-residue I-repeat motifs each with a helix-loop/span-helix structure; recombinant TFII-I binds independently to both Inr and E-box elements, and acts synergistically with USF1 to activate transcription in vivo through both elements of the adenovirus major late promoter.","method":"cDNA cloning, ectopic expression, DNA-binding assays, in vivo transcription reporter assays, domain analysis of USF1","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — primary structure determination plus multiple functional assays in same study","pmids":["9384587"],"is_preprint":false},{"year":1997,"finding":"TFII-I (identified as SPIN) interacts with serum response factor (SRF) and Phox1 in vitro and in vivo, promotes formation of stable higher-order SRF/Phox1/DNA complexes, and binds multiple sequences in the c-fos promoter to cooperate with Phox1 for serum-inducible transcription through the c-fos SRE.","method":"Protein purification, molecular cloning, in vitro binding assays, co-immunoprecipitation, cotransfection reporter assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical purification, reciprocal interaction assays, and functional reporter data in one study","pmids":["9334314"],"is_preprint":false},{"year":1997,"finding":"BAP-135 (TFII-I/GTF2I) is associated with Bruton's tyrosine kinase (Btk) in B cells via the Btk pleckstrin homology (PH) domain; it is a direct substrate for Btk-mediated tyrosine phosphorylation and is transiently phosphorylated on tyrosine following BCR crosslinking.","method":"Co-immunoprecipitation, in vitro kinase assay, PH domain binding mapping, BCR crosslinking experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay plus co-IP with domain mapping and physiological BCR stimulation","pmids":["9012831"],"is_preprint":false},{"year":1998,"finding":"TFII-I is required for efficient expression of the TATA-less, Inr-containing murine T-cell receptor Vβ5.2 promoter in vivo; an N-terminal protease-resistant DNA-binding fragment (p70) acts as a dominant negative inhibitor of Inr-specific function, demonstrating that the Inr-specific transcriptional function of TFII-I is dictated by its N-terminal domain and not its C-terminal activation domain.","method":"Transient transfection reporter assays, dominant-negative mutant analysis, ectopic expression of N-terminal fragment","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional dissection with dominant-negative and truncation mutants, single lab","pmids":["9671454"],"is_preprint":false},{"year":1998,"finding":"TFII-I is phosphorylated in vivo on both serine/threonine and tyrosine residues basally; mutation of a consensus tyrosine phosphorylation site severely reduces TFII-I-mediated basal transcriptional activation of the Vβ promoter in vivo, while phosphorylation does not affect DNA binding.","method":"In vivo phosphorylation assays (metabolic labeling), site-directed mutagenesis, transcription reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus functional read-out, single lab","pmids":["9837922"],"is_preprint":false},{"year":1998,"finding":"TFII-I enhances c-fos promoter activation through binding to the SIE and SRE upstream elements; it forms in vivo protein–protein complexes with SRF, STAT1, and STAT3; growth factor stimulation enhances tyrosine phosphorylation of TFII-I; and the Ras/MAPK pathway is required for TFII-I activity on the c-fos promoter.","method":"Co-immunoprecipitation, transient transfection reporter assays, site-directed mutagenesis, in vivo tyrosine phosphorylation assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus functional reporter assays, single lab","pmids":["9584171"],"is_preprint":false},{"year":1999,"finding":"TFII-I constitutively associates with wild-type and kinase-inactive Btk but not xid Btk (R28C PH domain mutation) in vivo; Btk's kinase domain is required to enhance TFII-I tyrosine phosphorylation and transcriptional activity; BCR crosslinking causes dissociation of TFII-I from Btk and increased nuclear import of TFII-I in wild-type but not xid B cells.","method":"Co-immunoprecipitation, transient transfection reporter assays, nuclear/cytoplasmic fractionation, BCR crosslinking","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP with domain mutants, subcellular fractionation, and functional transcription assays in physiological B cell context","pmids":["10373551"],"is_preprint":false},{"year":2000,"finding":"TFII-I forms stable homo- and heteromeric complexes via both its N-terminal region (containing a leucine zipper-like motif) and its I-repeats; complex formation aids nuclear translocation of TFII-I; co-expression of different isoforms leads to enhanced basal but attenuated signal-responsive transcriptional activity.","method":"Co-immunoprecipitation, nuclear/cytoplasmic fractionation, isoform-specific antibodies, reporter transcription assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple co-IP experiments with functional validation, single lab","pmids":["10854432"],"is_preprint":false},{"year":2000,"finding":"TFII-I has two distinct DNA-binding regions; deletion of either abolishes DNA binding and transcriptional activation; I-repeats mediate homomeric interactions individually or in combination; an additional homomeric interaction domain resides within the N-terminal leucine zipper region.","method":"Deletion mutagenesis, DNA-binding assays, transcription reporter assays, protein–protein interaction assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic mutagenesis with multiple assay read-outs, single lab","pmids":["11113127"],"is_preprint":false},{"year":2000,"finding":"ERK forms an in vivo complex with TFII-I through a consensus MAP kinase interaction domain (D-box) in TFII-I; ERK phosphorylates TFII-I in vitro at Ser627 and Ser633; mutation of the D-box or the ERK phosphorylation sites impairs TFII-I binding to ERK and its ability to enhance the c-fos promoter; serum stimulation enhances TFII-I–ERK complex formation.","method":"Co-immunoprecipitation, in vitro kinase assay, point mutagenesis, dominant-negative Ras, reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis plus functional reporter and co-IP in intact cells","pmids":["10648599"],"is_preprint":false},{"year":2001,"finding":"TFII-I is identified as the ERSE-binding factor (ERSF) that binds the ER stress response element (ERSE) in the grp78 and ERp72 promoters; purified recombinant TFII-I isoforms bind directly to ERSEs; ER stress (thapsigargin) increases TFII-I transcript and protein levels in the nucleus; TFII-I tyrosine phosphorylation sites are required for its activation of the Grp78 promoter; TFII-I physically interacts with ATF6 and is required for optimal ATF6-mediated ERSE stimulation.","method":"Chromatographic purification, protein microsequencing, recombinant protein binding assays, co-immunoprecipitation, reporter assays, stable knockdown","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical purification/sequencing to identify TFII-I as ERSF, recombinant protein direct binding, co-IP with ATF6, and functional mutagenesis","pmids":["11287625"],"is_preprint":false},{"year":2001,"finding":"JAK2 phosphorylates TFII-I at Tyr248 in vivo and in vitro; this phosphorylation event is required for TFII-I interaction with ERK and for TFII-I activity on the c-fos promoter; dominant-negative JAK2 or JAK2 inhibitor AG490 abolishes TFII-I activity on c-fos.","method":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis (Y248F), dominant-negative JAK2 expression, reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis plus co-IP and functional read-out","pmids":["11313464"],"is_preprint":false},{"year":2001,"finding":"Btk phosphorylates BAP/TFII-I predominantly at Tyr248, Tyr357, and Tyr462 in vitro and in vivo; mutation of any single site reduces c-fos promoter transcription, consistent with phosphorylation at these sites contributing to transcriptional activation.","method":"Site-directed mutagenesis, phosphopeptide mapping, in vitro kinase assay, co-expression with Btk in mammalian cells, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay combined with phosphopeptide mapping and site-directed mutagenesis with functional read-out","pmids":["11373296"],"is_preprint":false},{"year":2002,"finding":"HDAC3 copurifies with TFII-I in immunoaffinity purification, co-immunoprecipitates with TFII-I, and colocalizes with it; the HDAC3–TFII-I interaction requires the C-terminal region of HDAC3 (residues 373–401) and residues 363–606 of TFII-I; an anti-TFII-I immunoprecipitate contains HDAC3 enzymatic activity; overexpression of HDAC3 severely reduces TFII-I transcriptional activation.","method":"Immunoaffinity purification, co-immunoprecipitation, GST pull-down, indirect immunofluorescence colocalization, HDAC enzymatic activity assay, deletion mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods in one study identifying interaction and functional consequence","pmids":["12393887"],"is_preprint":false},{"year":2002,"finding":"TFII-I and HDAC3 physically and functionally interact; PIASxβ (an E3 SUMO ligase) interacts with both TFII-I and HDAC3, relieves HDAC3-mediated repression of TFII-I transcriptional activation, suggesting SUMO pathway cross-talk with histone deacetylation at TFII-I target promoters.","method":"Co-immunoprecipitation, subcellular colocalization, transcription reporter assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and functional reporter assays, single lab","pmids":["12239342"],"is_preprint":false},{"year":2002,"finding":"cGMP-dependent protein kinase Iβ (PKG Iβ) physically interacts with TFII-I via the N-terminal 93 amino acids of PKG Iβ and one of the six I-repeats of TFII-I; PKG phosphorylates TFII-I in vitro and in vivo at Ser371 and Ser743; mutation of these sites abolishes PKG-mediated enhancement of TFII-I transactivation of an SRE-containing promoter.","method":"Yeast two-hybrid screen, in vitro binding with purified recombinant proteins, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with mapped residues plus mutagenesis and functional reporter in intact cells","pmids":["12082086"],"is_preprint":false},{"year":2002,"finding":"PIASxβ/Miz1 (SUMO E3 ligase) interacts with TFII-I and with hMusTRD1/BEN; ectopic PIASxβ augments TFII-I transcriptional activity and relieves BEN-mediated repression; nuclear-localization-deficient PIASxβ fails to alter TFII-I subcellular localization.","method":"Yeast two-hybrid screen, co-immunoprecipitation in mammalian cells, reporter transcription assays, localization studies","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP and functional reporter, single lab","pmids":["12193603"],"is_preprint":false},{"year":2002,"finding":"c-Src phosphorylates TFII-I at Tyr248 and Tyr611 in a growth-factor-dependent manner; phosphorylated TFII-I translocates to the nucleus where it activates a stably integrated c-fos reporter; phosphorylation-deficient mutants (Y248F, Y611F) fail to activate the c-fos promoter; signal withdrawal leads to loss of nuclear TFII-I.","method":"In vivo tyrosine phosphorylation assays, site-directed mutagenesis, nuclear/cytoplasmic fractionation, stable c-fos reporter cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — stable reporter system with mutagenesis and fractionation, multiple orthogonal methods","pmids":["11934902"],"is_preprint":false},{"year":2001,"finding":"The TFII-I-related factor MusTRD1/BEN represses TFII-I transcriptional activity by excluding TFII-I from the nucleus when co-expressed; mutation of a nuclear localization signal in MusTRD1/BEN reverses this nuclear exclusion and restores c-fos promoter activity.","method":"Ectopic co-expression, subcellular localization (fluorescence microscopy), nuclear/cytoplasmic fractionation, reporter assays, NLS mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — localization experiments with functional consequence, mutagenesis validation, single lab","pmids":["11438732"],"is_preprint":false},{"year":2003,"finding":"The N-terminal ~90-amino acid region of TFII-I (including a leucine zipper motif) is primarily responsible for its physical interaction with Btk; Btk tethers TFII-I to the cytoplasm by preventing dimerization and nuclear localization; Src-dependent TFII-I tyrosine phosphorylation sites are distinct from those targeted by Btk, indicating two independent kinase pathways converge on TFII-I.","method":"Structural analysis with TFII-I deletion/point mutants, co-immunoprecipitation, nuclear/cytoplasmic fractionation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic domain mapping by co-IP with multiple mutants, single lab","pmids":["14623887"],"is_preprint":false},{"year":2005,"finding":"TFII-I forms a complex with Smad2 upon TGFβ/activin stimulation, is recruited to the distal element (DE) of the goosecoid (Gsc) promoter, and activates Gsc transcription; siRNA knockdown of TFII-I abolishes TGFβ-mediated Gsc induction; in Xenopus, antisense knockdown of TFII-I decreases Gsc expression; BEN constitutively occupies the DE in the absence of TGFβ and is replaced by the TFII-I/Smad2 complex upon stimulation.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, siRNA knockdown, reporter assays, Xenopus antisense experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, co-IP, siRNA knockdown, and in vivo Xenopus model, multiple orthogonal methods","pmids":["16055724"],"is_preprint":false},{"year":2005,"finding":"TGFβ1 stimulates TFII-I phosphorylation at Ser371 and Ser743; mutation of these sites (S371A/S743A) enhances complex formation between TFII-I and Smad3 and increases their cooperative transcriptional regulation of cyclin D2, cyclin D3, and E2F2 genes.","method":"Phosphoproteome profiling, site-directed mutagenesis, co-immunoprecipitation, microarray expression analysis, luciferase reporter assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics with mutagenesis and functional validation, single lab","pmids":["16055503"],"is_preprint":false},{"year":2005,"finding":"TFII-I is phosphorylated at Tyr248 by c-Src in response to thapsigargin (ER stress); c-Src activation by ER stress stimulates Grp78 promoter activity via TFII-I; stable cells with suppressed TFII-I levels show reduced Grp78 induction; ChIP demonstrates enhanced TFII-I binding to the Grp78 promoter upon ER stress.","method":"In vivo phosphorylation assays (phospho-specific antibodies), stable TFII-I knockdown, chromatin immunoprecipitation, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, stable knockdown, phospho-specific assays, and reporter in one study","pmids":["15664986"],"is_preprint":false},{"year":2005,"finding":"TFII-I binds the VEGFR-2/KDR Inr element and three regulatory E-boxes in the VEGFR-2 promoter; siRNA-mediated reduction of TFII-I decreases endogenous VEGFR-2 expression; TFII-I can act at both basal Inr and upstream regulatory sites of the same promoter; TFII-IRD1 counter-regulates the same promoter.","method":"Gel shift assays, siRNA knockdown, reporter assays, mutagenesis of Inr and E-boxes","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of endogenous gene expression plus DNA-binding and reporter assays, single lab","pmids":["15941713"],"is_preprint":false},{"year":2005,"finding":"PKG Iβ interaction with TFII-I requires a cluster of acidic amino acids in the PKG Iβ N-terminal leucine zipper (D26/E31); mutation D26K/E31R abrogates binding to TFII-I; basic residues in TFII-I within a putative α-helical region mediate binding to PKG Iβ.","method":"Site-directed mutagenesis, in vitro binding assays with purified proteins, co-immunoprecipitation in intact cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro binding with mutagenesis confirmed by co-IP, single lab","pmids":["16166082"],"is_preprint":false},{"year":2006,"finding":"TFII-I acts outside the nucleus as a negative regulator of agonist-induced calcium entry (ACE) by suppressing surface accumulation of TRPC3 channels; this inhibition requires phosphotyrosine residues that engage SH2 domains of PLCγ and a PH-like domain of TFII-I that binds the split PH domain of PLCγ, suggesting TFII-I competes with TRPC3 for PLCγ binding.","method":"Calcium entry assays, surface expression of TRPC3, domain mapping, phosphotyrosine-dependent interaction assays with PLCγ SH2 domains","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — cytoplasmic function defined by domain-specific interactions with mechanistic read-out (calcium entry), published in high-impact journal","pmids":["17023658"],"is_preprint":false},{"year":2006,"finding":"TFII-I directly interacts with Bright/ARID3a through Bright's protein interaction domain; specific tyrosine residues of TFII-I are essential for Bright-induced immunoglobulin reporter gene activity; TFII-I knockdown in B cells reduces heavy-chain transcript levels.","method":"Co-immunoprecipitation, siRNA knockdown, reporter assays, site-directed mutagenesis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with functional knockdown and mutagenesis, single lab","pmids":["16738337"],"is_preprint":false},{"year":2007,"finding":"TFII-I promotes B cell growth arrest in a signal-dependent manner by controlling c-Myc transcription and regulating NF-κB; loss of TFII-I function leads to up-regulation of c-Myc and down-regulation of p21 and p27, as well as increased nuclear c-rel and decreased p50 NF-κB DNA-binding activity.","method":"Stable post-transcriptional silencing (shRNA), immunoblotting, EMSA for NF-κB subunits, cell proliferation/apoptosis assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable knockdown with multiple molecular read-outs, single lab","pmids":["17312101"],"is_preprint":false},{"year":2007,"finding":"USF1, USF2, and TFII-I bind cooperatively to the HIV-1 LTR RBEIII element and are required for induction of latent integrated HIV-1 in response to T-cell receptor signaling; TFII-I stimulates USF1/USF2 binding to RBEIII ~160-fold less efficiently without TFII-I; dominant-interfering TFII-I inhibits induction; MAPK pathway is essential for induction.","method":"Electrophoretic mobility shift assay, chromatin immunoprecipitation, dominant-interfering constructs, T-cell receptor crosslinking, MEK inhibitor treatment","journal":"Virus genes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and EMSA with dominant-negative and pharmacological inhibition, replicated across related studies","pmids":["17546494","15767439"],"is_preprint":false},{"year":2008,"finding":"TFII-I forms a complex with PARP1 and SFPQ that binds to the DYX1C1 promoter SNP rs3743205; electrophoretic mobility shift assays show allele-specific TFII-I binding; luciferase assays show allelic differences in DYX1C1 promoter activity linked to the TFII-I binding site.","method":"Electrophoretic mobility shift assay, mass spectrometry identification of protein complex, protein sequencing, luciferase reporter assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical purification/MS identification of complex plus functional reporter assays, single lab","pmids":["18445785"],"is_preprint":false},{"year":2009,"finding":"TFII-I is recruited to the cyclin D1 promoter under normal growth conditions and transcriptionally activates it; upon genotoxic stress and p53 activation, TFII-I is ubiquitinated and degraded by the proteasome in a p53- and ATM-dependent manner; stable TFII-I expression increases cyclin D1 levels, accelerates S-phase entry/exit, and overcomes p53-mediated cell cycle arrest; these effects require tyrosine phosphorylation at Tyr248 and Tyr611.","method":"Chromatin immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, stable cell lines, flow cytometry, site-directed mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, ubiquitination assays, stable cells with mutagenesis, and cell cycle read-out, multiple orthogonal methods","pmids":["16314517"],"is_preprint":false},{"year":2009,"finding":"TFII-I silencing causes unexpected defects in S-phase progression (delay entering and executing S-phase and entry into G2/M); microarray and functional validation identify cyclin D1 and PKC-β as major downstream transcriptional targets; Cdk1 phosphorylates TFII-I at the G2/M boundary, likely displacing it from condensed chromatin.","method":"siRNA knockdown, flow cytometry (cell cycle analysis), microarray, functional validation assays, Cdk1 phosphorylation assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown with cell cycle read-out and microarray-validated targets, single lab","pmids":["19182516"],"is_preprint":false},{"year":2009,"finding":"Inducible tyrosine kinase (Itk) physically interacts with TFII-I in T cells; Itk phosphorylates TFII-I upon T-cell receptor crosslinking; kinase-dead or R29C mutant Itk fails to phosphorylate TFII-I; Itk potentiates TFII-I-driven c-fos transcription; the first 90 N-terminal residues of TFII-I are dispensable for Itk binding.","method":"Co-immunoprecipitation, phosphorylation assays (TCR crosslinking), dominant-negative Itk expression, reporter assays, N-terminal deletion mapping","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with kinase-dead controls and functional reporter, single lab","pmids":["19701889"],"is_preprint":false},{"year":2011,"finding":"OCA-B directly interacts with TFII-I (which binds DICE elements in Igh promoters); OCA-B relieves HDAC3-mediated Igh promoter repression by competing with HDAC3 for binding to promoter-bound TFII-I; Igh 3' enhancer-bound OCA-B and promoter-bound TFII-I mediate promoter–enhancer looping interactions in both cis and trans, required for Igh transcription.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, chromosome conformation capture (looping assay), reporter assays, competition binding assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including 3C/looping assay, co-IP, and ChIP with functional read-out","pmids":["21549311"],"is_preprint":false},{"year":2014,"finding":"Rev7 (regulatory subunit of Pol ζ) binds to TFII-I; TFII-I is required for translesion synthesis (TLS) and DNA damage tolerance independent of its transcription function; TLS function of TFII-I requires homodimerization and binding to PCNA, suggesting TFII-I bridges PCNA and Pol ζ.","method":"Co-immunoprecipitation, TLS functional assays, homodimerization mutants, PCNA-binding assays","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with functional TLS assays and domain requirements, single lab","pmids":["24922507"],"is_preprint":false},{"year":2015,"finding":"TFII-I interacts with CTCF in a distinct chromatin-bound complex; TFII-I is essential for directing CTCF binding to promoter-proximal regions of metabolic genes across the genome; knockdown of TFII-I reduces CTCF binding, diminishes CDK8 recruitment, and attenuates RNA Pol II Ser5 phosphorylation at co-regulated genes.","method":"Mass spectrometry of CTCF interactors, biochemical fractionation, ChIP-seq, siRNA knockdown, Pol II phosphorylation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — MS-identified interaction confirmed by biochemical fractionation and ChIP-seq genome-wide with functional validation","pmids":["25646466"],"is_preprint":false},{"year":2015,"finding":"TFII-I is SUMOylated at K221 and K240 by SUMO1; PIAS4 acts as the E3 ligase for TFII-I SUMOylation; SENP2 deSUMOylates TFII-I; SUMOylation reduces TFII-I binding to HDAC3, thereby promoting TFII-I transcriptional activity; SUMOylation is critical for TFII-I-driven cell proliferation and colony formation.","method":"Large-scale proteomics/IP-Western blot validation, site-directed mutagenesis (K221R, K240R), immunoprecipitation, cell proliferation assays, colony formation assays","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — modification site mapping with functional mutagenesis and cellular phenotype, single lab","pmids":["25869096"],"is_preprint":false},{"year":2016,"finding":"Adenovirus E4-ORF3 stimulates SUMOylation of TFII-I early during infection, then triggers its ubiquitination and proteasomal degradation; E4-ORF3 is required for TFII-I ubiquitination; degradation of TFII-I by E4-ORF3 stimulates activity of a TFII-I-repressed viral promoter.","method":"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, reporter assays, infection experiments","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — viral infection system with biochemical and functional read-outs, single lab","pmids":["26814176"],"is_preprint":false},{"year":2019,"finding":"Selective deletion of Gtf2i in excitatory neurons of the mouse forebrain causes reduced mature oligodendrocyte numbers, reduced myelin thickness, and impaired axonal conductivity; ~70% of genes with decreased mRNA in mutant cortex are myelination-related; restoring myelination with clemastine or increasing axonal conductivity rescued the behavioral deficits (increased sociability, fine motor deficits, anxiety).","method":"Conditional neuron-specific knockout, mRNA-seq, electron microscopy of myelin, electrophysiology, pharmacological rescue with clemastine","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific knockout with multiple orthogonal molecular and cellular read-outs plus pharmacological rescue, replicated in human WS cortex","pmids":["31011227"],"is_preprint":false},{"year":2023,"finding":"GTF2I dosage controls dynamics of neural progenitor proliferation and excitatory neuron differentiation in cortical organoids; 7q11.23 duplication (extra GTF2I copy) causes precocious excitatory neuron production rescued by restoring physiological GTF2I levels; GTF2I acts through LSD1 (lysine demethylase 1) as a downstream effector, and LSD1 inhibition rescues ASD-like behaviors in transgenic Gtf2i-duplication mice.","method":"Patient-derived cortical organoids, single-cell RNA-seq, proteomics, transgenic mouse model, LSD1 inhibitor treatment, behavioral assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — human organoids with single-cell resolution plus transgenic mice and pharmacological epistasis defining GTF2I–LSD1 pathway","pmids":["38019906"],"is_preprint":false},{"year":2020,"finding":"The GTF2I L424H knock-in mutation in thymic epithelial cells causes cell transformation, aneuploidy, and increased tumor growth; mutant TFII-I upregulates glycolytic enzymes and cyclooxygenase-2 (COX-2), and COX-2 upregulation is required for cell survival under metabolic stress and for cellular transformation.","method":"Gtf2i L424H knock-in cells, transcriptome analysis, cell transformation assays, COX-2 functional inhibition, metabolic stress assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockin model with functional rescue (COX-2 inhibition) establishing pathway, single lab","pmids":["32034314"],"is_preprint":false},{"year":2022,"finding":"Conditional knock-in of Gtf2i L424H in Foxn1+ thymic epithelial cells impairs thymic medulla development and maturation of medullary thymic epithelial cells (mTECs), causes enrichment of E2F/MYC target gene signatures, and leads to thymoma formation in aged mice, establishing the mutation as a driver of thymic epithelial transformation.","method":"Conditional knock-in mouse model, digital spatial transcriptomic profiling (GeoMx), immunohistochemistry, TCR repertoire analysis","journal":"Journal of thoracic oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional knock-in with spatial transcriptomics, single lab","pmids":["36049655"],"is_preprint":false},{"year":2008,"finding":"TFII-I interacts with Elongin A (identified by pull-down assay); TFII-I binds upstream and downstream of transcription start sites at active and repressed genes respectively; at the ATF3 stress-responsive gene, TFII-I is required for induction of transcription and correlates with increased Pol II and Elongin A association, implicating TFII-I in transcription elongation.","method":"Biotinylation-tagging ChIP-seq, pull-down assays, siRNA knockdown, Pol II/Elongin A ChIP","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq with pull-down and knockdown validation, single lab","pmids":["24875474"],"is_preprint":false}],"current_model":"TFII-I (GTF2I) is a signal-activated multifunctional transcription factor that binds Inr and E-box elements to regulate both TATA-less and signal-induced promoters; it shuttles between cytoplasm and nucleus in response to phosphorylation by multiple tyrosine kinases (Btk, Itk, JAK2, c-Src) at key residues (Y248, Y357, Y462, Y611) and serine kinases (ERK, PKG Iβ, Cdk1) that modulate its transcriptional activity, nuclear localization, protein–protein interactions, and cell-cycle control; outside the nucleus it suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding; it is regulated post-translationally by HDAC3-mediated repression, PIASxβ/SUMO-pathway activation, p53/ATM-dependent ubiquitin–proteasomal degradation, and PIAS4-mediated SUMOylation; it forms functional complexes with CTCF (directing genome-wide CTCF promoter occupancy), Smad2/3 (TGFβ signaling), ATF6 (ER stress), OCA-B (Igh enhancer–promoter looping), Rev7/PCNA (translesion DNA synthesis), and LSD1 (neural differentiation); haploinsufficiency causes Williams-Beuren syndrome neurocognitive features including myelination defects linked to reduced oligodendrocyte maturation, while the recurrent L424H missense mutation drives thymic epithelial transformation via COX-2 upregulation and altered metabolic gene expression."},"narrative":{"mechanistic_narrative":"GTF2I encodes TFII-I, a signal-responsive multifunctional transcription factor that defines an alternative, TFIID-dependent transcription initiation pathway by binding directly to initiator (Inr) elements at TATA-less promoters and cooperating with TBP to nucleate distinct preinitiation complexes [PMID:8377828]. Through its tandem I-repeats and two separable DNA-binding regions, TFII-I recognizes both Inr and E-box elements and acts at basal and upstream regulatory sites of the same gene, often synergizing with partner factors such as USF1 [PMID:9384587, PMID:11113127, PMID:15941713]. It integrates growth-factor and stress signaling at immediate-early and signal-induced promoters—most extensively the c-fos SRE/SIE, which it activates in complex with SRF, Phox1, STAT1/STAT3 and the Ras/MAPK pathway [PMID:9334314, PMID:9584171]. Its activity is gated by an unusually dense post-translational network: cytoplasmic-to-nuclear shuttling and transactivation are driven by tyrosine phosphorylation from Btk, Itk, JAK2 and c-Src at residues including Y248, Y357, Y462 and Y611, and by serine phosphorylation from ERK (S627/S633), PKG Iβ (S371/S743) and Cdk1, while Btk and the related repressor MusTRD1/BEN tether or exclude it from the nucleus [PMID:10373551, PMID:10648599, PMID:11313464, PMID:11373296, PMID:12082086, PMID:11934902, PMID:14623887, PMID:19701889, PMID:11438732]. TFII-I transcriptional output is further tuned by HDAC3-mediated repression, which is relieved by PIASxβ and by PIAS4-driven SUMOylation at K221/K240 that weakens HDAC3 binding, and the protein is targeted for p53/ATM-dependent ubiquitin–proteasomal degradation upon genotoxic stress [PMID:12393887, PMID:12239342, PMID:25869096, PMID:16314517]. Beyond core promoter control, TFII-I links to broad genome organization and signaling: it partners with CTCF to direct promoter-proximal CTCF occupancy and Pol II Ser5 phosphorylation at metabolic genes, mediates Igh enhancer–promoter looping with OCA-B, transduces TGFβ signals via Smad2/3, mediates the ER stress response as the ERSE-binding factor acting with ATF6, drives cyclin D1-dependent S-phase progression, and supports translesion DNA synthesis by bridging PCNA and Pol ζ via Rev7 [PMID:25646466, PMID:21549311, PMID:16055724, PMID:11287625, PMID:16314517, PMID:19182516, PMID:24922507]. Outside the nucleus, TFII-I suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding [PMID:17023658]. Haploinsufficiency and dosage imbalance of GTF2I underlie Williams-Beuren syndrome neurocognitive and myelination phenotypes, acting in part through an LSD1-dependent program controlling neural progenitor proliferation and oligodendrocyte maturation, while the recurrent L424H mutation drives thymic epithelial transformation through COX-2 and metabolic gene upregulation [PMID:31011227, PMID:38019906, PMID:32034314, PMID:36049655].","teleology":[{"year":1993,"claim":"Established that TFII-I is not merely an accessory factor but defines a distinct initiation pathway, answering how TATA-less, Inr-containing promoters recruit the basal machinery.","evidence":"In vitro transcription reconstitution and preinitiation complex assembly with defined factors","pmids":["8377828"],"confidence":"High","gaps":["Did not identify physiological target promoters in vivo","Structural basis of Inr recognition undefined"]},{"year":1993,"claim":"Showed the TFII-I initiation pathway is a regulatable node by demonstrating Myc selectively blocks TFII-I-dependent (not TFIIA-dependent) preinitiation, framing TFII-I as a target of oncogenic control.","evidence":"In vitro transcription and PIC formation assays with co-IP","pmids":["8377829"],"confidence":"High","gaps":["Physiological promoters subject to Myc–TFII-I antagonism not defined","In vivo relevance not tested"]},{"year":1997,"claim":"Defined TFII-I primary structure (six I-repeats) and dual Inr/E-box DNA-binding capacity, and connected it to upstream factors (USF1, SRF, Phox1) at serum-responsive promoters, explaining how one protein bridges core and enhancer elements.","evidence":"cDNA cloning, domain analysis, DNA-binding and reporter assays, biochemical purification (as SPIN)","pmids":["9384587","9334314"],"confidence":"High","gaps":["Mechanism of E-box vs Inr selectivity unresolved","No structural model of I-repeats"]},{"year":1997,"claim":"Linked TFII-I to receptor signaling by identifying it as a Btk-associated Btk substrate phosphorylated upon BCR crosslinking, opening the kinase-regulated dimension of its biology.","evidence":"Co-IP, in vitro kinase assay, PH-domain binding mapping, BCR crosslinking","pmids":["9012831"],"confidence":"High","gaps":["Functional consequence of phosphorylation not yet shown","Which tyrosines phosphorylated not mapped here"]},{"year":1998,"claim":"Showed Inr-specific transcriptional function resides in the N-terminal DNA-binding domain and that tyrosine phosphorylation modulates transactivation without affecting DNA binding, separating recruitment from activation.","evidence":"Dominant-negative truncation mutants, in vivo phosphorylation labeling, reporter assays on the TCR Vβ promoter","pmids":["9671454","9837922"],"confidence":"Medium","gaps":["Single-lab functional dissection","Specific kinases for basal phosphorylation not identified"]},{"year":1999,"claim":"Defined the cytoplasm–nucleus shuttling logic: Btk tethers TFII-I in the cytoplasm and BCR signaling dissociates the complex to permit nuclear import, establishing signal-gated subcellular localization.","evidence":"Co-IP with Btk domain mutants, subcellular fractionation, BCR crosslinking, reporter assays","pmids":["10373551"],"confidence":"High","gaps":["Import receptor / NLS machinery not defined","Quantitative kinetics of shuttling unknown"]},{"year":2000,"claim":"Resolved the structural determinants of oligomerization and DNA binding, showing self-association via the N-terminal leucine zipper and I-repeats aids nuclear translocation and tunes basal vs signal-responsive output.","evidence":"Deletion/point mutagenesis, co-IP, fractionation, reporter assays","pmids":["10854432","11113127"],"confidence":"Medium","gaps":["Stoichiometry of homo/heteromers undefined","Isoform-specific roles incompletely mapped"]},{"year":2000,"claim":"Connected TFII-I to MAPK signaling mechanistically by mapping an ERK docking D-box and ERK phosphorylation sites (S627/S633) required for c-fos activation.","evidence":"Co-IP, in vitro kinase assay, point mutagenesis, dominant-negative Ras, reporter assays","pmids":["10648599"],"confidence":"High","gaps":["How serine phosphorylation alters complex assembly not detailed"]},{"year":2001,"claim":"Identified TFII-I as the ER stress response element-binding factor (ERSF) acting with ATF6, extending its role to the unfolded protein response at grp78/ERp72 promoters.","evidence":"Chromatographic purification, microsequencing, recombinant binding, co-IP with ATF6, knockdown, reporter assays","pmids":["11287625"],"confidence":"High","gaps":["How ER stress signal reaches TFII-I not defined here"]},{"year":2001,"claim":"Mapped specific tyrosine kinases (JAK2 at Y248; Btk at Y248/Y357/Y462) to defined residues required for c-fos activity, dissecting which inputs converge on which sites.","evidence":"In vitro kinase assays, phosphopeptide mapping, site-directed mutagenesis, dominant-negative JAK2, reporter assays","pmids":["11313464","11373296"],"confidence":"High","gaps":["Combinatorial logic of multi-site phosphorylation untested","Spatial/temporal ordering of kinase action unknown"]},{"year":2001,"claim":"Showed the TFII-I-related repressor MusTRD1/BEN antagonizes TFII-I by NLS-dependent nuclear exclusion, identifying a paralog-based regulatory switch.","evidence":"Co-expression, localization microscopy, fractionation, NLS mutagenesis, reporter assays","pmids":["11438732"],"confidence":"Medium","gaps":["Single-lab study","In vivo physiological context of antagonism not established"]},{"year":2002,"claim":"Established the repressive arm of TFII-I regulation by identifying HDAC3 as a bound deacetylase that suppresses transactivation, and PIASxβ/SUMO pathway as a relieving counterforce.","evidence":"Immunoaffinity purification, co-IP, GST pulldown, HDAC activity assay, reporter assays","pmids":["12393887","12239342","12193603"],"confidence":"High","gaps":["Direct demonstration that SUMOylation displaces HDAC3 came later","Genome-wide target promoters of repression not mapped"]},{"year":2002,"claim":"Extended kinase regulation to serine/threonine and second-messenger pathways by mapping PKG Iβ phosphorylation at S371/S743 and c-Src phosphorylation at Y248/Y611 driving nuclear translocation.","evidence":"Yeast two-hybrid, in vitro kinase assays, mutagenesis, fractionation, stable c-fos reporter cells","pmids":["12082086","11934902"],"confidence":"High","gaps":["Crosstalk between Ser and Tyr modifications not integrated","Stoichiometry in vivo unknown"]},{"year":2003,"claim":"Clarified that Btk and Src target distinct sites and that Btk tethers TFII-I cytoplasmically by preventing dimerization, showing parallel kinase pathways converge with opposing localization outcomes.","evidence":"Domain mapping with deletion/point mutants, co-IP, fractionation","pmids":["14623887"],"confidence":"Medium","gaps":["Single-lab domain study","Whether dimerization-coupled import is direct mechanism untested structurally"]},{"year":2005,"claim":"Defined TFII-I as a signal-recruited Smad partner in TGFβ/activin signaling controlling developmental and cell-cycle genes, with Ser371/S743 phosphorylation tuning Smad complex formation.","evidence":"Co-IP, ChIP, siRNA knockdown, Xenopus antisense, microarray, reporter assays","pmids":["16055724","16055503"],"confidence":"High","gaps":["Direct vs cofactor-mediated DNA contact at Gsc DE not resolved","How phosphorylation alters Smad affinity mechanistically unclear"]},{"year":2005,"claim":"Demonstrated dual Inr/E-box action on endogenous promoters (VEGFR-2) and that c-Src phosphorylation at Y248 couples ER stress to Grp78 induction, unifying its DNA-binding versatility with signal input.","evidence":"Gel shift, siRNA, reporter/mutagenesis, ChIP, phospho-specific antibodies, stable knockdown","pmids":["15941713","15664986"],"confidence":"Medium","gaps":["Counter-regulation by TFII-IRD1 mechanism incomplete","Generality across other Inr/E-box genes untested"]},{"year":2006,"claim":"Revealed a non-transcriptional cytoplasmic function: TFII-I suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding, expanding its role beyond the nucleus.","evidence":"Calcium entry assays, TRPC3 surface expression, PLCγ SH2/PH-domain interaction mapping","pmids":["17023658"],"confidence":"High","gaps":["In vivo physiological calcium contexts not established","Reciprocal regulation of nuclear vs cytoplasmic pools unclear"]},{"year":2006,"claim":"Connected TFII-I to immunoglobulin gene regulation in B cells through ARID3a/Bright interaction and tyrosine-dependent heavy-chain transcription.","evidence":"Co-IP, siRNA knockdown, reporter assays, mutagenesis","pmids":["16738337"],"confidence":"Medium","gaps":["Single-lab study","Mechanism of looping not yet shown (later defined via OCA-B)"]},{"year":2007,"claim":"Established a role in B-cell growth control, with TFII-I restraining c-Myc and modulating NF-κB and CDK inhibitors during signal-dependent growth arrest.","evidence":"shRNA silencing, immunoblotting, EMSA for NF-κB subunits, proliferation/apoptosis assays","pmids":["17312101"],"confidence":"Medium","gaps":["Direct vs indirect transcriptional effects on c-Myc/NF-κB not separated","Single-lab data"]},{"year":2007,"claim":"Showed TFII-I cooperates with USF1/USF2 to reactivate latent integrated HIV-1 via the LTR RBEIII element in a TCR/MAPK-dependent manner, extending its enhancer cooperativity to viral transcription.","evidence":"EMSA, ChIP, dominant-interfering constructs, TCR crosslinking, MEK inhibition","pmids":["17546494","15767439"],"confidence":"Medium","gaps":["Quantitative contribution to latency reversal in primary cells not assessed"]},{"year":2008,"claim":"Implicated TFII-I in dyslexia-associated regulatory variation by showing allele-specific binding within a PARP1/SFPQ complex at the DYX1C1 promoter SNP.","evidence":"EMSA, MS identification, protein sequencing, luciferase reporter assays","pmids":["18445785"],"confidence":"Medium","gaps":["Causal link to dyslexia phenotype not established","Functional role of PARP1/SFPQ partnership undefined"]},{"year":2008,"claim":"Extended TFII-I function to transcription elongation by demonstrating Elongin A interaction and Pol II/Elongin A-coupled recruitment at the stress-responsive ATF3 gene genome-wide.","evidence":"Biotinylation-tagging ChIP-seq, pulldown, siRNA, Pol II/Elongin A ChIP","pmids":["24875474"],"confidence":"Medium","gaps":["Direct mechanistic role in elongation vs recruitment not resolved","Single-lab genome-wide dataset"]},{"year":2009,"claim":"Defined TFII-I as a cell-cycle regulator: it activates cyclin D1 to promote S-phase progression, is degraded by p53/ATM-dependent ubiquitination upon genotoxic stress, and is phosphorylated by Cdk1 at the G2/M boundary.","evidence":"ChIP, ubiquitination/proteasome assays, stable cells, flow cytometry, mutagenesis, microarray","pmids":["16314517","19182516"],"confidence":"High","gaps":["E3 ligase mediating p53-dependent degradation not identified","Direct Cdk1 site on TFII-I not mapped here"]},{"year":2009,"claim":"Identified Itk as an additional T-cell tyrosine kinase phosphorylating TFII-I downstream of TCR engagement to potentiate c-fos transcription.","evidence":"Co-IP, TCR-crosslinking phosphorylation, kinase-dead/R29C mutants, reporter assays, deletion mapping","pmids":["19701889"],"confidence":"Medium","gaps":["Itk target tyrosines not mapped","Redundancy with Btk in B vs T cells unresolved"]},{"year":2011,"claim":"Provided a 3D chromatin mechanism for Igh regulation: promoter-bound TFII-I and enhancer-bound OCA-B mediate enhancer–promoter looping, with OCA-B relieving HDAC3 repression by competing for TFII-I.","evidence":"Co-IP, ChIP, chromosome conformation capture, competition binding, reporter assays","pmids":["21549311"],"confidence":"High","gaps":["Generality of TFII-I-mediated looping at other loci untested"]},{"year":2014,"claim":"Revealed a transcription-independent genome-maintenance role: TFII-I bridges PCNA and Pol ζ via Rev7 to support translesion synthesis and DNA damage tolerance.","evidence":"Co-IP, TLS functional assays, homodimerization and PCNA-binding mutants","pmids":["24922507"],"confidence":"Medium","gaps":["Structural basis of the PCNA–Pol ζ bridge undefined","Single-lab study"]},{"year":2015,"claim":"Placed TFII-I in genome organization by showing it directs CTCF promoter-proximal occupancy and Pol II Ser5 phosphorylation at metabolic genes, and refined its PTM logic by defining PIAS4-mediated SUMOylation at K221/K240 that antagonizes HDAC3 binding.","evidence":"MS of CTCF interactors, fractionation, ChIP-seq, siRNA; SUMO site mapping, mutagenesis, proliferation/colony assays","pmids":["25646466","25869096"],"confidence":"High","gaps":["Whether TFII-I recruits or stabilizes CTCF mechanistically unclear","Link between SUMO and CTCF arms not integrated"]},{"year":2016,"claim":"Showed viral exploitation of TFII-I turnover: adenovirus E4-ORF3 first stimulates SUMOylation then drives ubiquitin–proteasomal degradation of TFII-I to derepress a viral promoter.","evidence":"Co-IP, ubiquitination/proteasome assays, reporter assays, infection","pmids":["26814176"],"confidence":"Medium","gaps":["E3 ligase for E4-ORF3-induced degradation not identified","Single virus context"]},{"year":2019,"claim":"Established a causal neurodevelopmental mechanism for Williams-Beuren features: neuronal Gtf2i loss reduces oligodendrocyte maturation and myelination, with deficits rescued pharmacologically.","evidence":"Neuron-specific conditional knockout, mRNA-seq, EM myelin imaging, electrophysiology, clemastine rescue","pmids":["31011227"],"confidence":"High","gaps":["Direct transcriptional targets driving myelination program not pinpointed","Cell-autonomous vs non-autonomous signal to oligodendrocytes unresolved"]},{"year":2023,"claim":"Defined the dosage-sensitive neurodevelopmental program and effector: GTF2I controls cortical progenitor proliferation and neuron differentiation through LSD1, with LSD1 inhibition rescuing duplication-driven phenotypes.","evidence":"Patient-derived cortical organoids, scRNA-seq, proteomics, transgenic mice, LSD1 inhibitor, behavioral assays","pmids":["38019906"],"confidence":"High","gaps":["Direct biochemical GTF2I–LSD1 mechanism at chromatin not fully mapped","Generalizability across patient genetic backgrounds untested"]},{"year":2020,"claim":"Identified the oncogenic mechanism of the recurrent L424H mutation in thymic epithelium: mutant TFII-I upregulates COX-2 and glycolytic genes required for transformation and survival under metabolic stress.","evidence":"L424H knock-in cells, transcriptomics, transformation assays, COX-2 inhibition, metabolic stress assays","pmids":["32034314"],"confidence":"Medium","gaps":["How L424H alters DNA binding/specificity not defined","Single-lab cellular model"]},{"year":2022,"claim":"Confirmed L424H as an in vivo thymic oncogenic driver, impairing medullary thymic epithelial maturation and driving E2F/MYC-associated thymoma in aged mice.","evidence":"Conditional Foxn1-driven knock-in mouse, spatial transcriptomics, IHC, TCR repertoire analysis","pmids":["36049655"],"confidence":"Medium","gaps":["Mechanistic link from L424H to E2F/MYC signature not dissected","Long latency mechanism unexplained"]},{"year":null,"claim":"How TFII-I integrates its dense multi-kinase, SUMO, ubiquitin, and acetylation inputs into a unified code that selects among its many DNA-binding, looping, calcium-suppressing, and DNA-repair functions remains unresolved at the structural and quantitative level.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of full-length TFII-I or its I-repeat DNA complexes","Combinatorial PTM logic governing function selection undefined","Mechanism by which L424H rewires specificity toward oncogenic programs unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,7,12,22,25,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,10,25]},{"term_id":"GO:0140223","term_label":"general transcription initiation factor activity","supporting_discovery_ids":[0]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[35,36,37]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[27]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,9,19,20,32]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,21,27]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[12,35,37]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,3,7,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,13,22,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[32,33]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[12,24]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[36]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[35,37]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[40,41]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,8,28,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[40,42,43]}],"complexes":["TFII-I/CTCF chromatin complex","TFII-I/Smad2/3 complex","TFII-I/OCA-B Igh looping complex","TFII-I/PARP1/SFPQ complex"],"partners":["BTK","ERK/MAPK1","JAK2","SRC","HDAC3","ATF6","CTCF","SMAD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P78347","full_name":"General transcription factor II-I","aliases":["Bruton tyrosine kinase-associated protein 135","BAP-135","BTK-associated protein 135","SRF-Phox1-interacting protein","SPIN","Williams-Beuren syndrome chromosomal region 6 protein"],"length_aa":998,"mass_kda":112.4,"function":"Interacts with the basal transcription machinery by coordinating the formation of a multiprotein complex at the C-FOS promoter, and linking specific signal responsive activator complexes. Promotes the formation of stable high-order complexes of SRF and PHOX1 and interacts cooperatively with PHOX1 to promote serum-inducible transcription of a reporter gene deriven by the C-FOS serum response element (SRE). Acts as a coregulator for USF1 by binding independently two promoter elements, a pyrimidine-rich initiator (Inr) and an upstream E-box. Required for the formation of functional ARID3A DNA-binding complexes and for activation of immunoglobulin heavy-chain transcription upon B-lymphocyte activation","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P78347/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GTF2I","classification":"Not Classified","n_dependent_lines":70,"n_total_lines":1208,"dependency_fraction":0.057947019867549666},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"KPNA4","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GTF2I","total_profiled":1310},"omim":[{"mim_id":"616886","title":"GSE1 COILED-COIL PROTEIN; GSE1","url":"https://www.omim.org/entry/616886"},{"mim_id":"611240","title":"GPRIN FAMILY, MEMBER 2; GPRIN2","url":"https://www.omim.org/entry/611240"},{"mim_id":"610813","title":"HYDIN AXONEMAL CENTRAL PAIR APPARATUS PROTEIN 2; HYDIN2","url":"https://www.omim.org/entry/610813"},{"mim_id":"610501","title":"NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 1; NBPF1","url":"https://www.omim.org/entry/610501"},{"mim_id":"609757","title":"WILLIAMS-BEUREN REGION DUPLICATION SYNDROME","url":"https://www.omim.org/entry/609757"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GTF2I"},"hgnc":{"alias_symbol":["TFII-I","BAP-135","SPIN","BTKAP1","DIWS","IB291"],"prev_symbol":["WBSCR6"]},"alphafold":{"accession":"P78347","domains":[{"cath_id":"3.90.1460.10","chopping":"129-187","consensus_level":"medium","plddt":88.0531,"start":129,"end":187},{"cath_id":"3.90.1460.10","chopping":"455-542","consensus_level":"medium","plddt":88.4999,"start":455,"end":542},{"cath_id":"3.90.1460.10","chopping":"564-659","consensus_level":"medium","plddt":87.852,"start":564,"end":659},{"cath_id":"3.90.1460.10","chopping":"722-806","consensus_level":"medium","plddt":89.4259,"start":722,"end":806},{"cath_id":"3.90.1460.10","chopping":"859-939","consensus_level":"high","plddt":89.7789,"start":859,"end":939},{"cath_id":"3.40.1810","chopping":"18-92","consensus_level":"high","plddt":84.0388,"start":18,"end":92}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78347","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78347-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78347-F1-predicted_aligned_error_v6.png","plddt_mean":68.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GTF2I","jax_strain_url":"https://www.jax.org/strain/search?query=GTF2I"},"sequence":{"accession":"P78347","fasta_url":"https://rest.uniprot.org/uniprotkb/P78347.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78347/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78347"}},"corpus_meta":[{"pmid":"8377829","id":"PMC_8377829","title":"Direct role for Myc in transcription initiation mediated by interactions with TFII-I.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8377829","citation_count":252,"is_preprint":false},{"pmid":"24974848","id":"PMC_24974848","title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24974848","citation_count":218,"is_preprint":false},{"pmid":"9384587","id":"PMC_9384587","title":"Cloning of an inr- and E-box-binding protein, TFII-I, that interacts physically and functionally with USF1.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9384587","citation_count":175,"is_preprint":false},{"pmid":"8377828","id":"PMC_8377828","title":"An alternative pathway for transcription initiation involving TFII-I.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8377828","citation_count":153,"is_preprint":false},{"pmid":"9012831","id":"PMC_9012831","title":"BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9012831","citation_count":149,"is_preprint":false},{"pmid":"9466987","id":"PMC_9466987","title":"A duplicated gene in the breakpoint regions of the 7q11.23 Williams-Beuren syndrome deletion encodes the initiator binding protein TFII-I and BAP-135, a phosphorylation target of BTK.","date":"1998","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9466987","citation_count":139,"is_preprint":false},{"pmid":"14556246","id":"PMC_14556246","title":"GTF2I hemizygosity implicated in mental retardation in Williams syndrome: genotype-phenotype analysis of five families with deletions in the Williams syndrome region.","date":"2003","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/14556246","citation_count":128,"is_preprint":false},{"pmid":"9334314","id":"PMC_9334314","title":"A multifunctional DNA-binding protein that promotes the formation of serum response factor/homeodomain complexes: identity to TFII-I.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9334314","citation_count":119,"is_preprint":false},{"pmid":"9584171","id":"PMC_9584171","title":"TFII-I enhances activation of the c-fos promoter through interactions with upstream elements.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9584171","citation_count":101,"is_preprint":false},{"pmid":"19109438","id":"PMC_19109438","title":"Essential functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic development.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19109438","citation_count":99,"is_preprint":false},{"pmid":"11674993","id":"PMC_11674993","title":"Biochemistry and biology of the inducible multifunctional transcription factor TFII-I.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11674993","citation_count":97,"is_preprint":false},{"pmid":"31011227","id":"PMC_31011227","title":"Neuronal deletion of Gtf2i, associated with Williams syndrome, causes behavioral and myelin alterations rescuable by a remyelinating drug.","date":"2019","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31011227","citation_count":97,"is_preprint":false},{"pmid":"19897463","id":"PMC_19897463","title":"Partial 7q11.23 deletions further implicate GTF2I and GTF2IRD1 as the main genes responsible for the Williams-Beuren syndrome neurocognitive profile.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19897463","citation_count":97,"is_preprint":false},{"pmid":"12865760","id":"PMC_12865760","title":"Williams syndrome deficits in visual spatial processing linked to GTF2IRD1 and GTF2I on chromosome 7q11.23.","date":"2003","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12865760","citation_count":94,"is_preprint":false},{"pmid":"11287625","id":"PMC_11287625","title":"Identification of TFII-I as the endoplasmic reticulum stress response element binding factor ERSF: its autoregulation by stress and interaction with ATF6.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11287625","citation_count":92,"is_preprint":false},{"pmid":"10373551","id":"PMC_10373551","title":"Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10373551","citation_count":91,"is_preprint":false},{"pmid":"19205026","id":"PMC_19205026","title":"Is it Williams syndrome? GTF2IRD1 implicated in visual-spatial construction and GTF2I in sociability revealed by high resolution arrays.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19205026","citation_count":88,"is_preprint":false},{"pmid":"21328569","id":"PMC_21328569","title":"Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions.","date":"2010","source":"Autism research : official journal of the International Society for Autism Research","url":"https://pubmed.ncbi.nlm.nih.gov/21328569","citation_count":85,"is_preprint":false},{"pmid":"17023658","id":"PMC_17023658","title":"Action of TFII-I outside the nucleus as an inhibitor of agonist-induced calcium entry.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17023658","citation_count":80,"is_preprint":false},{"pmid":"12239342","id":"PMC_12239342","title":"Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12239342","citation_count":79,"is_preprint":false},{"pmid":"15664986","id":"PMC_15664986","title":"Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress: role of TFII-I and its tyrosine phosphorylation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15664986","citation_count":65,"is_preprint":false},{"pmid":"10861001","id":"PMC_10861001","title":"Isolation and characterization of BEN, a member of the TFII-I family of DNA-binding proteins containing distinct helix-loop-helix domains.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10861001","citation_count":62,"is_preprint":false},{"pmid":"25646466","id":"PMC_25646466","title":"Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25646466","citation_count":60,"is_preprint":false},{"pmid":"22578324","id":"PMC_22578324","title":"Duplication of GTF2I results in separation anxiety in mice and humans.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22578324","citation_count":59,"is_preprint":false},{"pmid":"18445785","id":"PMC_18445785","title":"The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia.","date":"2008","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18445785","citation_count":59,"is_preprint":false},{"pmid":"12082086","id":"PMC_12082086","title":"cGMP-dependent protein kinase I beta physically and functionally interacts with the transcriptional regulator TFII-I.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12082086","citation_count":56,"is_preprint":false},{"pmid":"12393887","id":"PMC_12393887","title":"Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12393887","citation_count":56,"is_preprint":false},{"pmid":"9671454","id":"PMC_9671454","title":"TFII-I regulates Vbeta promoter activity through an initiator element.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9671454","citation_count":56,"is_preprint":false},{"pmid":"10648599","id":"PMC_10648599","title":"Extracellular signal-regulated kinase binds to TFII-I and regulates its activation of the c-fos promoter.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10648599","citation_count":53,"is_preprint":false},{"pmid":"21549311","id":"PMC_21549311","title":"Direct interactions of OCA-B and TFII-I regulate immunoglobulin heavy-chain gene transcription by facilitating enhancer-promoter communication.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21549311","citation_count":52,"is_preprint":false},{"pmid":"16738337","id":"PMC_16738337","title":"Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16738337","citation_count":52,"is_preprint":false},{"pmid":"22048961","id":"PMC_22048961","title":"Association of GTF2i in the Williams-Beuren syndrome critical region with autism spectrum disorders.","date":"2012","source":"Journal of autism and developmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22048961","citation_count":51,"is_preprint":false},{"pmid":"10854432","id":"PMC_10854432","title":"Alternatively spliced isoforms of TFII-I. Complex formation, nuclear translocation, and differential gene regulation.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10854432","citation_count":50,"is_preprint":false},{"pmid":"11934902","id":"PMC_11934902","title":"c-Src-dependent transcriptional activation of TFII-I.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11934902","citation_count":50,"is_preprint":false},{"pmid":"17976384","id":"PMC_17976384","title":"Signal-induced functions of the transcription factor TFII-I.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17976384","citation_count":48,"is_preprint":false},{"pmid":"17546494","id":"PMC_17546494","title":"Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling.","date":"2007","source":"Virus genes","url":"https://pubmed.ncbi.nlm.nih.gov/17546494","citation_count":47,"is_preprint":false},{"pmid":"15100712","id":"PMC_15100712","title":"Isolation and characterisation of GTF2IRD2, a novel fusion gene and member of the TFII-I family of transcription factors, deleted in Williams-Beuren syndrome.","date":"2004","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15100712","citation_count":45,"is_preprint":false},{"pmid":"15767439","id":"PMC_15767439","title":"TFII-I regulates induction of chromosomally integrated human immunodeficiency virus type 1 long terminal repeat in cooperation with USF.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15767439","citation_count":45,"is_preprint":false},{"pmid":"28461154","id":"PMC_28461154","title":"Pathophysiology of TFII-I: Old Guard Wearing New Hats.","date":"2017","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28461154","citation_count":44,"is_preprint":false},{"pmid":"9837922","id":"PMC_9837922","title":"Regulation of TFII-I activity by phosphorylation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9837922","citation_count":43,"is_preprint":false},{"pmid":"8901589","id":"PMC_8901589","title":"NF-kappa B homodimer binding within the HIV-1 initiator region and interactions with TFII-I.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8901589","citation_count":42,"is_preprint":false},{"pmid":"18579769","id":"PMC_18579769","title":"Identification of the TFII-I family target genes in the vertebrate genome.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18579769","citation_count":40,"is_preprint":false},{"pmid":"15388857","id":"PMC_15388857","title":"Comparison of TFII-I gene family members deleted in Williams-Beuren syndrome.","date":"2004","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/15388857","citation_count":38,"is_preprint":false},{"pmid":"16055503","id":"PMC_16055503","title":"Phosphoproteome profiling of transforming growth factor (TGF)-beta signaling: abrogation of TGFbeta1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16055503","citation_count":38,"is_preprint":false},{"pmid":"16055724","id":"PMC_16055724","title":"Positive and negative regulation of the transforming growth factor beta/activin target gene goosecoid by the TFII-I family of transcription factors.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16055724","citation_count":38,"is_preprint":false},{"pmid":"24922507","id":"PMC_24922507","title":"The transcription factor TFII-I promotes DNA translesion synthesis and genomic stability.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24922507","citation_count":37,"is_preprint":false},{"pmid":"14645227","id":"PMC_14645227","title":"Regulation of immunoglobulin promoter activity by TFII-I class transcription factors.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14645227","citation_count":36,"is_preprint":false},{"pmid":"9521869","id":"PMC_9521869","title":"A mouse single-copy gene, Gtf2i, the homolog of human GTF2I, that is duplicated in the Williams-Beuren syndrome deletion region.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9521869","citation_count":35,"is_preprint":false},{"pmid":"8530424","id":"PMC_8530424","title":"The TATA-less promoter of mouse ribonucleotide reductase R1 gene contains a TFII-I binding initiator element essential for cell cycle-regulated transcription.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8530424","citation_count":35,"is_preprint":false},{"pmid":"16314517","id":"PMC_16314517","title":"Inhibition of TFII-I-dependent cell cycle regulation by p53.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16314517","citation_count":34,"is_preprint":false},{"pmid":"10642537","id":"PMC_10642537","title":"Characterization and gene structure of a novel retinoblastoma-protein-associated protein similar to the transcription regulator TFII-I.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10642537","citation_count":34,"is_preprint":false},{"pmid":"28448514","id":"PMC_28448514","title":"A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28448514","citation_count":33,"is_preprint":false},{"pmid":"11113127","id":"PMC_11113127","title":"Structure-function analysis of TFII-I. Roles of the N-terminal end, basic region, and I-repeats.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11113127","citation_count":33,"is_preprint":false},{"pmid":"24933421","id":"PMC_24933421","title":"17β-Estradiol inhibits ER stress-induced apoptosis through promotion of TFII-I-dependent Grp78 induction in osteoblasts.","date":"2014","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24933421","citation_count":33,"is_preprint":false},{"pmid":"26216516","id":"PMC_26216516","title":"Intracisternal Gtf2i Gene Therapy Ameliorates Deficits in Cognition and Synaptic Plasticity of a Mouse Model of Williams-Beuren Syndrome.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26216516","citation_count":32,"is_preprint":false},{"pmid":"14751286","id":"PMC_14751286","title":"TFII-I, a candidate gene for Williams syndrome cognitive profile: parallels between regional expression in mouse brain and human phenotype.","date":"2004","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14751286","citation_count":32,"is_preprint":false},{"pmid":"15941713","id":"PMC_15941713","title":"Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15941713","citation_count":31,"is_preprint":false},{"pmid":"19097122","id":"PMC_19097122","title":"Transcription factor TFII-I causes transcriptional upregulation of GRP78 synthesis in prostate cancer cells.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19097122","citation_count":31,"is_preprint":false},{"pmid":"25429715","id":"PMC_25429715","title":"Cognitive-behavioral phenotypes of Williams syndrome are associated with genetic variation in the GTF2I gene, in a healthy population.","date":"2014","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25429715","citation_count":31,"is_preprint":false},{"pmid":"32034314","id":"PMC_32034314","title":"Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/32034314","citation_count":30,"is_preprint":false},{"pmid":"38019906","id":"PMC_38019906","title":"GTF2I dosage regulates neuronal differentiation and social behavior in 7q11.23 neurodevelopmental disorders.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38019906","citation_count":30,"is_preprint":false},{"pmid":"9915861","id":"PMC_9915861","title":"The human KDR/flk-1 gene contains a functional initiator element that is bound and transactivated by TFII-I.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9915861","citation_count":30,"is_preprint":false},{"pmid":"16223582","id":"PMC_16223582","title":"TFII-I and USF (RBF-2) regulate Ras/MAPK-responsive HIV-1 transcription in T cells.","date":"2005","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16223582","citation_count":29,"is_preprint":false},{"pmid":"20403157","id":"PMC_20403157","title":"Essential role of the N-terminal region of TFII-I in viability and behavior.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20403157","citation_count":29,"is_preprint":false},{"pmid":"11827466","id":"PMC_11827466","title":"Genomic organization of the genes Gtf2ird1, Gtf2i, and Ncf1 at the mouse chromosome 5 region syntenic to the human chromosome 7q11.23 Williams syndrome critical region.","date":"2002","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11827466","citation_count":29,"is_preprint":false},{"pmid":"11313464","id":"PMC_11313464","title":"JAK2 activates TFII-I and regulates its interaction with extracellular signal-regulated kinase.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11313464","citation_count":28,"is_preprint":false},{"pmid":"12193603","id":"PMC_12193603","title":"The SUMO ubiquitin-protein isopeptide ligase family member Miz1/PIASxbeta /Siz2 is a transcriptional cofactor for TFII-I.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12193603","citation_count":28,"is_preprint":false},{"pmid":"16166082","id":"PMC_16166082","title":"Identification of the interface between cGMP-dependent protein kinase Ibeta and its interaction partners TFII-I and IRAG reveals a common interaction motif.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16166082","citation_count":28,"is_preprint":false},{"pmid":"11438732","id":"PMC_11438732","title":"Repression of TFII-I-dependent transcription by nuclear exclusion.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11438732","citation_count":26,"is_preprint":false},{"pmid":"26285132","id":"PMC_26285132","title":"Variation in the Williams syndrome GTF2I gene and anxiety proneness interactively affect prefrontal cortical response to aversive stimuli.","date":"2015","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26285132","citation_count":25,"is_preprint":false},{"pmid":"15987678","id":"PMC_15987678","title":"Multiple GTF2I-like repeats of general transcription factor 3 exhibit DNA binding properties. Evidence for a common origin as a sequence-specific DNA interaction module.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15987678","citation_count":25,"is_preprint":false},{"pmid":"20500075","id":"PMC_20500075","title":"Molecular basis of Williams-Beuren syndrome: TFII-I regulated targets involved in craniofacial development.","date":"2010","source":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","url":"https://pubmed.ncbi.nlm.nih.gov/20500075","citation_count":25,"is_preprint":false},{"pmid":"32313931","id":"PMC_32313931","title":"Functions of Gtf2i and Gtf2ird1 in the developing brain: transcription, DNA binding and long-term behavioral consequences.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32313931","citation_count":24,"is_preprint":false},{"pmid":"21407215","id":"PMC_21407215","title":"Multifunctional transcription factor TFII-I is an activator of BRCA1 function.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21407215","citation_count":24,"is_preprint":false},{"pmid":"12971990","id":"PMC_12971990","title":"Expression of BEN, a member of TFII-I family of transcription factors, during mouse pre- and postimplantation development.","date":"2003","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12971990","citation_count":24,"is_preprint":false},{"pmid":"19701889","id":"PMC_19701889","title":"Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19701889","citation_count":24,"is_preprint":false},{"pmid":"18976654","id":"PMC_18976654","title":"Specific interaction of TFII-I with an upstream element on the HIV-1 LTR regulates induction of latent provirus.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18976654","citation_count":24,"is_preprint":false},{"pmid":"32722121","id":"PMC_32722121","title":"Primary Driver Mutations in GTF2I Specific to the Development of Thymomas.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32722121","citation_count":23,"is_preprint":false},{"pmid":"15243160","id":"PMC_15243160","title":"GTF2IRD2 is located in the Williams-Beuren syndrome critical region 7q11.23 and encodes a protein with two TFII-I-like helix-loop-helix repeats.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15243160","citation_count":23,"is_preprint":false},{"pmid":"28424317","id":"PMC_28424317","title":"The Williams syndrome prosociality gene GTF2I mediates oxytocin reactivity and social anxiety in a healthy population.","date":"2017","source":"Biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28424317","citation_count":22,"is_preprint":false},{"pmid":"11373296","id":"PMC_11373296","title":"Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11373296","citation_count":22,"is_preprint":false},{"pmid":"25869096","id":"PMC_25869096","title":"Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation.","date":"2015","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/25869096","citation_count":22,"is_preprint":false},{"pmid":"26814176","id":"PMC_26814176","title":"The Adenovirus E4-ORF3 Protein Stimulates SUMOylation of General Transcription Factor TFII-I to Direct Proteasomal Degradation.","date":"2016","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/26814176","citation_count":22,"is_preprint":false},{"pmid":"31418010","id":"PMC_31418010","title":"Gtf2i and Gtf2ird1 mutation do not account for the full phenotypic effect of the Williams syndrome critical region in mouse models.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31418010","citation_count":21,"is_preprint":false},{"pmid":"14623887","id":"PMC_14623887","title":"Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14623887","citation_count":21,"is_preprint":false},{"pmid":"17970752","id":"PMC_17970752","title":"Recruitment of coregulator complexes to the beta-globin gene locus by TFII-I and upstream stimulatory factor.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17970752","citation_count":21,"is_preprint":false},{"pmid":"22970219","id":"PMC_22970219","title":"Diversity and complexity in chromatin recognition by TFII-I transcription factors in pluripotent embryonic stem cells and embryonic tissues.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22970219","citation_count":21,"is_preprint":false},{"pmid":"17823943","id":"PMC_17823943","title":"TFII-I gene family during tooth development: candidate genes for tooth anomalies in Williams syndrome.","date":"2007","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17823943","citation_count":20,"is_preprint":false},{"pmid":"19182516","id":"PMC_19182516","title":"Phase specific functions of the transcription factor TFII-I during cell cycle.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19182516","citation_count":20,"is_preprint":false},{"pmid":"14678824","id":"PMC_14678824","title":"The early embryonic expression of TFII-I during mouse preimplantation development.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/14678824","citation_count":20,"is_preprint":false},{"pmid":"36049655","id":"PMC_36049655","title":"A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation.","date":"2022","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36049655","citation_count":19,"is_preprint":false},{"pmid":"24875474","id":"PMC_24875474","title":"Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24875474","citation_count":19,"is_preprint":false},{"pmid":"33208191","id":"PMC_33208191","title":"High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons.","date":"2020","source":"Molecular autism","url":"https://pubmed.ncbi.nlm.nih.gov/33208191","citation_count":19,"is_preprint":false},{"pmid":"29305905","id":"PMC_29305905","title":"The contribution of GTF2I haploinsufficiency to Williams syndrome.","date":"2018","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/29305905","citation_count":18,"is_preprint":false},{"pmid":"36175547","id":"PMC_36175547","title":"Human thymoma-associated mutation of the GTF2I transcription factor impairs thymic epithelial progenitor differentiation in mice.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36175547","citation_count":18,"is_preprint":false},{"pmid":"16611241","id":"PMC_16611241","title":"TFII-I down-regulates a subset of estrogen-responsive genes through its interaction with an initiator element and estrogen receptor alpha.","date":"2006","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/16611241","citation_count":18,"is_preprint":false},{"pmid":"9237169","id":"PMC_9237169","title":"Methods for studying the biochemical properties of an Inr element binding protein: TFII-I.","date":"1997","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/9237169","citation_count":18,"is_preprint":false},{"pmid":"17312101","id":"PMC_17312101","title":"Cutting Edge: TFII-I controls B cell proliferation via regulating NF-kappaB.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17312101","citation_count":17,"is_preprint":false},{"pmid":"19880526","id":"PMC_19880526","title":"Williams-Beuren syndrome-associated transcription factor TFII-I regulates osteogenic marker genes.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19880526","citation_count":17,"is_preprint":false},{"pmid":"23831514","id":"PMC_23831514","title":"TFII-I regulates target genes in the PI-3K and TGF-β signaling pathways through a novel DNA binding motif.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23831514","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46619,"output_tokens":11262,"usd":0.154393,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22013,"output_tokens":9207,"usd":0.17012,"stage2_stop_reason":"end_turn"},"total_usd":0.324513,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"TFII-I defines an alternative transcription initiation pathway through direct binding to the initiator (Inr) element, forming preinitiation complexes distinct from those formed with TFIIA; TBP binds cooperatively with TFII-I at Inr-containing TATA-less promoters, enabling a TFIID-dependent pathway at TATA-less promoters.\",\n      \"method\": \"In vitro transcription reconstitution, preinitiation complex assembly assays, sequential factor addition\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro transcription pathway with defined factors, published in two companion papers from Roeder lab\",\n      \"pmids\": [\"8377828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Myc interacts physically with TFII-I and inhibits TFII-I-dependent transcription initiation selectively, correlating with prevention of TBP–TFII-I–promoter complex formation; this inhibition is specific to the TFII-I-dependent (not TFIIA-dependent) initiation pathway.\",\n      \"method\": \"In vitro transcription assay, protein–protein interaction (co-immunoprecipitation/pulldown), preinitiation complex formation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with functional read-out and mechanistic dissection of pathway specificity\",\n      \"pmids\": [\"8377829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TFII-I encodes a 120 kDa polypeptide containing six directly repeated ~90-residue I-repeat motifs each with a helix-loop/span-helix structure; recombinant TFII-I binds independently to both Inr and E-box elements, and acts synergistically with USF1 to activate transcription in vivo through both elements of the adenovirus major late promoter.\",\n      \"method\": \"cDNA cloning, ectopic expression, DNA-binding assays, in vivo transcription reporter assays, domain analysis of USF1\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — primary structure determination plus multiple functional assays in same study\",\n      \"pmids\": [\"9384587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TFII-I (identified as SPIN) interacts with serum response factor (SRF) and Phox1 in vitro and in vivo, promotes formation of stable higher-order SRF/Phox1/DNA complexes, and binds multiple sequences in the c-fos promoter to cooperate with Phox1 for serum-inducible transcription through the c-fos SRE.\",\n      \"method\": \"Protein purification, molecular cloning, in vitro binding assays, co-immunoprecipitation, cotransfection reporter assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical purification, reciprocal interaction assays, and functional reporter data in one study\",\n      \"pmids\": [\"9334314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BAP-135 (TFII-I/GTF2I) is associated with Bruton's tyrosine kinase (Btk) in B cells via the Btk pleckstrin homology (PH) domain; it is a direct substrate for Btk-mediated tyrosine phosphorylation and is transiently phosphorylated on tyrosine following BCR crosslinking.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, PH domain binding mapping, BCR crosslinking experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay plus co-IP with domain mapping and physiological BCR stimulation\",\n      \"pmids\": [\"9012831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TFII-I is required for efficient expression of the TATA-less, Inr-containing murine T-cell receptor Vβ5.2 promoter in vivo; an N-terminal protease-resistant DNA-binding fragment (p70) acts as a dominant negative inhibitor of Inr-specific function, demonstrating that the Inr-specific transcriptional function of TFII-I is dictated by its N-terminal domain and not its C-terminal activation domain.\",\n      \"method\": \"Transient transfection reporter assays, dominant-negative mutant analysis, ectopic expression of N-terminal fragment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional dissection with dominant-negative and truncation mutants, single lab\",\n      \"pmids\": [\"9671454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TFII-I is phosphorylated in vivo on both serine/threonine and tyrosine residues basally; mutation of a consensus tyrosine phosphorylation site severely reduces TFII-I-mediated basal transcriptional activation of the Vβ promoter in vivo, while phosphorylation does not affect DNA binding.\",\n      \"method\": \"In vivo phosphorylation assays (metabolic labeling), site-directed mutagenesis, transcription reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus functional read-out, single lab\",\n      \"pmids\": [\"9837922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TFII-I enhances c-fos promoter activation through binding to the SIE and SRE upstream elements; it forms in vivo protein–protein complexes with SRF, STAT1, and STAT3; growth factor stimulation enhances tyrosine phosphorylation of TFII-I; and the Ras/MAPK pathway is required for TFII-I activity on the c-fos promoter.\",\n      \"method\": \"Co-immunoprecipitation, transient transfection reporter assays, site-directed mutagenesis, in vivo tyrosine phosphorylation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus functional reporter assays, single lab\",\n      \"pmids\": [\"9584171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TFII-I constitutively associates with wild-type and kinase-inactive Btk but not xid Btk (R28C PH domain mutation) in vivo; Btk's kinase domain is required to enhance TFII-I tyrosine phosphorylation and transcriptional activity; BCR crosslinking causes dissociation of TFII-I from Btk and increased nuclear import of TFII-I in wild-type but not xid B cells.\",\n      \"method\": \"Co-immunoprecipitation, transient transfection reporter assays, nuclear/cytoplasmic fractionation, BCR crosslinking\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP with domain mutants, subcellular fractionation, and functional transcription assays in physiological B cell context\",\n      \"pmids\": [\"10373551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TFII-I forms stable homo- and heteromeric complexes via both its N-terminal region (containing a leucine zipper-like motif) and its I-repeats; complex formation aids nuclear translocation of TFII-I; co-expression of different isoforms leads to enhanced basal but attenuated signal-responsive transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, nuclear/cytoplasmic fractionation, isoform-specific antibodies, reporter transcription assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple co-IP experiments with functional validation, single lab\",\n      \"pmids\": [\"10854432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TFII-I has two distinct DNA-binding regions; deletion of either abolishes DNA binding and transcriptional activation; I-repeats mediate homomeric interactions individually or in combination; an additional homomeric interaction domain resides within the N-terminal leucine zipper region.\",\n      \"method\": \"Deletion mutagenesis, DNA-binding assays, transcription reporter assays, protein–protein interaction assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic mutagenesis with multiple assay read-outs, single lab\",\n      \"pmids\": [\"11113127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERK forms an in vivo complex with TFII-I through a consensus MAP kinase interaction domain (D-box) in TFII-I; ERK phosphorylates TFII-I in vitro at Ser627 and Ser633; mutation of the D-box or the ERK phosphorylation sites impairs TFII-I binding to ERK and its ability to enhance the c-fos promoter; serum stimulation enhances TFII-I–ERK complex formation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, point mutagenesis, dominant-negative Ras, reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis plus functional reporter and co-IP in intact cells\",\n      \"pmids\": [\"10648599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TFII-I is identified as the ERSE-binding factor (ERSF) that binds the ER stress response element (ERSE) in the grp78 and ERp72 promoters; purified recombinant TFII-I isoforms bind directly to ERSEs; ER stress (thapsigargin) increases TFII-I transcript and protein levels in the nucleus; TFII-I tyrosine phosphorylation sites are required for its activation of the Grp78 promoter; TFII-I physically interacts with ATF6 and is required for optimal ATF6-mediated ERSE stimulation.\",\n      \"method\": \"Chromatographic purification, protein microsequencing, recombinant protein binding assays, co-immunoprecipitation, reporter assays, stable knockdown\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical purification/sequencing to identify TFII-I as ERSF, recombinant protein direct binding, co-IP with ATF6, and functional mutagenesis\",\n      \"pmids\": [\"11287625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"JAK2 phosphorylates TFII-I at Tyr248 in vivo and in vitro; this phosphorylation event is required for TFII-I interaction with ERK and for TFII-I activity on the c-fos promoter; dominant-negative JAK2 or JAK2 inhibitor AG490 abolishes TFII-I activity on c-fos.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis (Y248F), dominant-negative JAK2 expression, reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis plus co-IP and functional read-out\",\n      \"pmids\": [\"11313464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Btk phosphorylates BAP/TFII-I predominantly at Tyr248, Tyr357, and Tyr462 in vitro and in vivo; mutation of any single site reduces c-fos promoter transcription, consistent with phosphorylation at these sites contributing to transcriptional activation.\",\n      \"method\": \"Site-directed mutagenesis, phosphopeptide mapping, in vitro kinase assay, co-expression with Btk in mammalian cells, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay combined with phosphopeptide mapping and site-directed mutagenesis with functional read-out\",\n      \"pmids\": [\"11373296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HDAC3 copurifies with TFII-I in immunoaffinity purification, co-immunoprecipitates with TFII-I, and colocalizes with it; the HDAC3–TFII-I interaction requires the C-terminal region of HDAC3 (residues 373–401) and residues 363–606 of TFII-I; an anti-TFII-I immunoprecipitate contains HDAC3 enzymatic activity; overexpression of HDAC3 severely reduces TFII-I transcriptional activation.\",\n      \"method\": \"Immunoaffinity purification, co-immunoprecipitation, GST pull-down, indirect immunofluorescence colocalization, HDAC enzymatic activity assay, deletion mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods in one study identifying interaction and functional consequence\",\n      \"pmids\": [\"12393887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TFII-I and HDAC3 physically and functionally interact; PIASxβ (an E3 SUMO ligase) interacts with both TFII-I and HDAC3, relieves HDAC3-mediated repression of TFII-I transcriptional activation, suggesting SUMO pathway cross-talk with histone deacetylation at TFII-I target promoters.\",\n      \"method\": \"Co-immunoprecipitation, subcellular colocalization, transcription reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and functional reporter assays, single lab\",\n      \"pmids\": [\"12239342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"cGMP-dependent protein kinase Iβ (PKG Iβ) physically interacts with TFII-I via the N-terminal 93 amino acids of PKG Iβ and one of the six I-repeats of TFII-I; PKG phosphorylates TFII-I in vitro and in vivo at Ser371 and Ser743; mutation of these sites abolishes PKG-mediated enhancement of TFII-I transactivation of an SRE-containing promoter.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding with purified recombinant proteins, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with mapped residues plus mutagenesis and functional reporter in intact cells\",\n      \"pmids\": [\"12082086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PIASxβ/Miz1 (SUMO E3 ligase) interacts with TFII-I and with hMusTRD1/BEN; ectopic PIASxβ augments TFII-I transcriptional activity and relieves BEN-mediated repression; nuclear-localization-deficient PIASxβ fails to alter TFII-I subcellular localization.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation in mammalian cells, reporter transcription assays, localization studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP and functional reporter, single lab\",\n      \"pmids\": [\"12193603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"c-Src phosphorylates TFII-I at Tyr248 and Tyr611 in a growth-factor-dependent manner; phosphorylated TFII-I translocates to the nucleus where it activates a stably integrated c-fos reporter; phosphorylation-deficient mutants (Y248F, Y611F) fail to activate the c-fos promoter; signal withdrawal leads to loss of nuclear TFII-I.\",\n      \"method\": \"In vivo tyrosine phosphorylation assays, site-directed mutagenesis, nuclear/cytoplasmic fractionation, stable c-fos reporter cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — stable reporter system with mutagenesis and fractionation, multiple orthogonal methods\",\n      \"pmids\": [\"11934902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The TFII-I-related factor MusTRD1/BEN represses TFII-I transcriptional activity by excluding TFII-I from the nucleus when co-expressed; mutation of a nuclear localization signal in MusTRD1/BEN reverses this nuclear exclusion and restores c-fos promoter activity.\",\n      \"method\": \"Ectopic co-expression, subcellular localization (fluorescence microscopy), nuclear/cytoplasmic fractionation, reporter assays, NLS mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — localization experiments with functional consequence, mutagenesis validation, single lab\",\n      \"pmids\": [\"11438732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The N-terminal ~90-amino acid region of TFII-I (including a leucine zipper motif) is primarily responsible for its physical interaction with Btk; Btk tethers TFII-I to the cytoplasm by preventing dimerization and nuclear localization; Src-dependent TFII-I tyrosine phosphorylation sites are distinct from those targeted by Btk, indicating two independent kinase pathways converge on TFII-I.\",\n      \"method\": \"Structural analysis with TFII-I deletion/point mutants, co-immunoprecipitation, nuclear/cytoplasmic fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic domain mapping by co-IP with multiple mutants, single lab\",\n      \"pmids\": [\"14623887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TFII-I forms a complex with Smad2 upon TGFβ/activin stimulation, is recruited to the distal element (DE) of the goosecoid (Gsc) promoter, and activates Gsc transcription; siRNA knockdown of TFII-I abolishes TGFβ-mediated Gsc induction; in Xenopus, antisense knockdown of TFII-I decreases Gsc expression; BEN constitutively occupies the DE in the absence of TGFβ and is replaced by the TFII-I/Smad2 complex upon stimulation.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, siRNA knockdown, reporter assays, Xenopus antisense experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, co-IP, siRNA knockdown, and in vivo Xenopus model, multiple orthogonal methods\",\n      \"pmids\": [\"16055724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TGFβ1 stimulates TFII-I phosphorylation at Ser371 and Ser743; mutation of these sites (S371A/S743A) enhances complex formation between TFII-I and Smad3 and increases their cooperative transcriptional regulation of cyclin D2, cyclin D3, and E2F2 genes.\",\n      \"method\": \"Phosphoproteome profiling, site-directed mutagenesis, co-immunoprecipitation, microarray expression analysis, luciferase reporter assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics with mutagenesis and functional validation, single lab\",\n      \"pmids\": [\"16055503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TFII-I is phosphorylated at Tyr248 by c-Src in response to thapsigargin (ER stress); c-Src activation by ER stress stimulates Grp78 promoter activity via TFII-I; stable cells with suppressed TFII-I levels show reduced Grp78 induction; ChIP demonstrates enhanced TFII-I binding to the Grp78 promoter upon ER stress.\",\n      \"method\": \"In vivo phosphorylation assays (phospho-specific antibodies), stable TFII-I knockdown, chromatin immunoprecipitation, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, stable knockdown, phospho-specific assays, and reporter in one study\",\n      \"pmids\": [\"15664986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TFII-I binds the VEGFR-2/KDR Inr element and three regulatory E-boxes in the VEGFR-2 promoter; siRNA-mediated reduction of TFII-I decreases endogenous VEGFR-2 expression; TFII-I can act at both basal Inr and upstream regulatory sites of the same promoter; TFII-IRD1 counter-regulates the same promoter.\",\n      \"method\": \"Gel shift assays, siRNA knockdown, reporter assays, mutagenesis of Inr and E-boxes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of endogenous gene expression plus DNA-binding and reporter assays, single lab\",\n      \"pmids\": [\"15941713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKG Iβ interaction with TFII-I requires a cluster of acidic amino acids in the PKG Iβ N-terminal leucine zipper (D26/E31); mutation D26K/E31R abrogates binding to TFII-I; basic residues in TFII-I within a putative α-helical region mediate binding to PKG Iβ.\",\n      \"method\": \"Site-directed mutagenesis, in vitro binding assays with purified proteins, co-immunoprecipitation in intact cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro binding with mutagenesis confirmed by co-IP, single lab\",\n      \"pmids\": [\"16166082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TFII-I acts outside the nucleus as a negative regulator of agonist-induced calcium entry (ACE) by suppressing surface accumulation of TRPC3 channels; this inhibition requires phosphotyrosine residues that engage SH2 domains of PLCγ and a PH-like domain of TFII-I that binds the split PH domain of PLCγ, suggesting TFII-I competes with TRPC3 for PLCγ binding.\",\n      \"method\": \"Calcium entry assays, surface expression of TRPC3, domain mapping, phosphotyrosine-dependent interaction assays with PLCγ SH2 domains\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cytoplasmic function defined by domain-specific interactions with mechanistic read-out (calcium entry), published in high-impact journal\",\n      \"pmids\": [\"17023658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TFII-I directly interacts with Bright/ARID3a through Bright's protein interaction domain; specific tyrosine residues of TFII-I are essential for Bright-induced immunoglobulin reporter gene activity; TFII-I knockdown in B cells reduces heavy-chain transcript levels.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, reporter assays, site-directed mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with functional knockdown and mutagenesis, single lab\",\n      \"pmids\": [\"16738337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TFII-I promotes B cell growth arrest in a signal-dependent manner by controlling c-Myc transcription and regulating NF-κB; loss of TFII-I function leads to up-regulation of c-Myc and down-regulation of p21 and p27, as well as increased nuclear c-rel and decreased p50 NF-κB DNA-binding activity.\",\n      \"method\": \"Stable post-transcriptional silencing (shRNA), immunoblotting, EMSA for NF-κB subunits, cell proliferation/apoptosis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable knockdown with multiple molecular read-outs, single lab\",\n      \"pmids\": [\"17312101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"USF1, USF2, and TFII-I bind cooperatively to the HIV-1 LTR RBEIII element and are required for induction of latent integrated HIV-1 in response to T-cell receptor signaling; TFII-I stimulates USF1/USF2 binding to RBEIII ~160-fold less efficiently without TFII-I; dominant-interfering TFII-I inhibits induction; MAPK pathway is essential for induction.\",\n      \"method\": \"Electrophoretic mobility shift assay, chromatin immunoprecipitation, dominant-interfering constructs, T-cell receptor crosslinking, MEK inhibitor treatment\",\n      \"journal\": \"Virus genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and EMSA with dominant-negative and pharmacological inhibition, replicated across related studies\",\n      \"pmids\": [\"17546494\", \"15767439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TFII-I forms a complex with PARP1 and SFPQ that binds to the DYX1C1 promoter SNP rs3743205; electrophoretic mobility shift assays show allele-specific TFII-I binding; luciferase assays show allelic differences in DYX1C1 promoter activity linked to the TFII-I binding site.\",\n      \"method\": \"Electrophoretic mobility shift assay, mass spectrometry identification of protein complex, protein sequencing, luciferase reporter assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical purification/MS identification of complex plus functional reporter assays, single lab\",\n      \"pmids\": [\"18445785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TFII-I is recruited to the cyclin D1 promoter under normal growth conditions and transcriptionally activates it; upon genotoxic stress and p53 activation, TFII-I is ubiquitinated and degraded by the proteasome in a p53- and ATM-dependent manner; stable TFII-I expression increases cyclin D1 levels, accelerates S-phase entry/exit, and overcomes p53-mediated cell cycle arrest; these effects require tyrosine phosphorylation at Tyr248 and Tyr611.\",\n      \"method\": \"Chromatin immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, stable cell lines, flow cytometry, site-directed mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, ubiquitination assays, stable cells with mutagenesis, and cell cycle read-out, multiple orthogonal methods\",\n      \"pmids\": [\"16314517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TFII-I silencing causes unexpected defects in S-phase progression (delay entering and executing S-phase and entry into G2/M); microarray and functional validation identify cyclin D1 and PKC-β as major downstream transcriptional targets; Cdk1 phosphorylates TFII-I at the G2/M boundary, likely displacing it from condensed chromatin.\",\n      \"method\": \"siRNA knockdown, flow cytometry (cell cycle analysis), microarray, functional validation assays, Cdk1 phosphorylation assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown with cell cycle read-out and microarray-validated targets, single lab\",\n      \"pmids\": [\"19182516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Inducible tyrosine kinase (Itk) physically interacts with TFII-I in T cells; Itk phosphorylates TFII-I upon T-cell receptor crosslinking; kinase-dead or R29C mutant Itk fails to phosphorylate TFII-I; Itk potentiates TFII-I-driven c-fos transcription; the first 90 N-terminal residues of TFII-I are dispensable for Itk binding.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays (TCR crosslinking), dominant-negative Itk expression, reporter assays, N-terminal deletion mapping\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with kinase-dead controls and functional reporter, single lab\",\n      \"pmids\": [\"19701889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"OCA-B directly interacts with TFII-I (which binds DICE elements in Igh promoters); OCA-B relieves HDAC3-mediated Igh promoter repression by competing with HDAC3 for binding to promoter-bound TFII-I; Igh 3' enhancer-bound OCA-B and promoter-bound TFII-I mediate promoter–enhancer looping interactions in both cis and trans, required for Igh transcription.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, chromosome conformation capture (looping assay), reporter assays, competition binding assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including 3C/looping assay, co-IP, and ChIP with functional read-out\",\n      \"pmids\": [\"21549311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rev7 (regulatory subunit of Pol ζ) binds to TFII-I; TFII-I is required for translesion synthesis (TLS) and DNA damage tolerance independent of its transcription function; TLS function of TFII-I requires homodimerization and binding to PCNA, suggesting TFII-I bridges PCNA and Pol ζ.\",\n      \"method\": \"Co-immunoprecipitation, TLS functional assays, homodimerization mutants, PCNA-binding assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with functional TLS assays and domain requirements, single lab\",\n      \"pmids\": [\"24922507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TFII-I interacts with CTCF in a distinct chromatin-bound complex; TFII-I is essential for directing CTCF binding to promoter-proximal regions of metabolic genes across the genome; knockdown of TFII-I reduces CTCF binding, diminishes CDK8 recruitment, and attenuates RNA Pol II Ser5 phosphorylation at co-regulated genes.\",\n      \"method\": \"Mass spectrometry of CTCF interactors, biochemical fractionation, ChIP-seq, siRNA knockdown, Pol II phosphorylation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — MS-identified interaction confirmed by biochemical fractionation and ChIP-seq genome-wide with functional validation\",\n      \"pmids\": [\"25646466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TFII-I is SUMOylated at K221 and K240 by SUMO1; PIAS4 acts as the E3 ligase for TFII-I SUMOylation; SENP2 deSUMOylates TFII-I; SUMOylation reduces TFII-I binding to HDAC3, thereby promoting TFII-I transcriptional activity; SUMOylation is critical for TFII-I-driven cell proliferation and colony formation.\",\n      \"method\": \"Large-scale proteomics/IP-Western blot validation, site-directed mutagenesis (K221R, K240R), immunoprecipitation, cell proliferation assays, colony formation assays\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — modification site mapping with functional mutagenesis and cellular phenotype, single lab\",\n      \"pmids\": [\"25869096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adenovirus E4-ORF3 stimulates SUMOylation of TFII-I early during infection, then triggers its ubiquitination and proteasomal degradation; E4-ORF3 is required for TFII-I ubiquitination; degradation of TFII-I by E4-ORF3 stimulates activity of a TFII-I-repressed viral promoter.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, reporter assays, infection experiments\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — viral infection system with biochemical and functional read-outs, single lab\",\n      \"pmids\": [\"26814176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Selective deletion of Gtf2i in excitatory neurons of the mouse forebrain causes reduced mature oligodendrocyte numbers, reduced myelin thickness, and impaired axonal conductivity; ~70% of genes with decreased mRNA in mutant cortex are myelination-related; restoring myelination with clemastine or increasing axonal conductivity rescued the behavioral deficits (increased sociability, fine motor deficits, anxiety).\",\n      \"method\": \"Conditional neuron-specific knockout, mRNA-seq, electron microscopy of myelin, electrophysiology, pharmacological rescue with clemastine\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific knockout with multiple orthogonal molecular and cellular read-outs plus pharmacological rescue, replicated in human WS cortex\",\n      \"pmids\": [\"31011227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GTF2I dosage controls dynamics of neural progenitor proliferation and excitatory neuron differentiation in cortical organoids; 7q11.23 duplication (extra GTF2I copy) causes precocious excitatory neuron production rescued by restoring physiological GTF2I levels; GTF2I acts through LSD1 (lysine demethylase 1) as a downstream effector, and LSD1 inhibition rescues ASD-like behaviors in transgenic Gtf2i-duplication mice.\",\n      \"method\": \"Patient-derived cortical organoids, single-cell RNA-seq, proteomics, transgenic mouse model, LSD1 inhibitor treatment, behavioral assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human organoids with single-cell resolution plus transgenic mice and pharmacological epistasis defining GTF2I–LSD1 pathway\",\n      \"pmids\": [\"38019906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The GTF2I L424H knock-in mutation in thymic epithelial cells causes cell transformation, aneuploidy, and increased tumor growth; mutant TFII-I upregulates glycolytic enzymes and cyclooxygenase-2 (COX-2), and COX-2 upregulation is required for cell survival under metabolic stress and for cellular transformation.\",\n      \"method\": \"Gtf2i L424H knock-in cells, transcriptome analysis, cell transformation assays, COX-2 functional inhibition, metabolic stress assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockin model with functional rescue (COX-2 inhibition) establishing pathway, single lab\",\n      \"pmids\": [\"32034314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Conditional knock-in of Gtf2i L424H in Foxn1+ thymic epithelial cells impairs thymic medulla development and maturation of medullary thymic epithelial cells (mTECs), causes enrichment of E2F/MYC target gene signatures, and leads to thymoma formation in aged mice, establishing the mutation as a driver of thymic epithelial transformation.\",\n      \"method\": \"Conditional knock-in mouse model, digital spatial transcriptomic profiling (GeoMx), immunohistochemistry, TCR repertoire analysis\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional knock-in with spatial transcriptomics, single lab\",\n      \"pmids\": [\"36049655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TFII-I interacts with Elongin A (identified by pull-down assay); TFII-I binds upstream and downstream of transcription start sites at active and repressed genes respectively; at the ATF3 stress-responsive gene, TFII-I is required for induction of transcription and correlates with increased Pol II and Elongin A association, implicating TFII-I in transcription elongation.\",\n      \"method\": \"Biotinylation-tagging ChIP-seq, pull-down assays, siRNA knockdown, Pol II/Elongin A ChIP\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq with pull-down and knockdown validation, single lab\",\n      \"pmids\": [\"24875474\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFII-I (GTF2I) is a signal-activated multifunctional transcription factor that binds Inr and E-box elements to regulate both TATA-less and signal-induced promoters; it shuttles between cytoplasm and nucleus in response to phosphorylation by multiple tyrosine kinases (Btk, Itk, JAK2, c-Src) at key residues (Y248, Y357, Y462, Y611) and serine kinases (ERK, PKG Iβ, Cdk1) that modulate its transcriptional activity, nuclear localization, protein–protein interactions, and cell-cycle control; outside the nucleus it suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding; it is regulated post-translationally by HDAC3-mediated repression, PIASxβ/SUMO-pathway activation, p53/ATM-dependent ubiquitin–proteasomal degradation, and PIAS4-mediated SUMOylation; it forms functional complexes with CTCF (directing genome-wide CTCF promoter occupancy), Smad2/3 (TGFβ signaling), ATF6 (ER stress), OCA-B (Igh enhancer–promoter looping), Rev7/PCNA (translesion DNA synthesis), and LSD1 (neural differentiation); haploinsufficiency causes Williams-Beuren syndrome neurocognitive features including myelination defects linked to reduced oligodendrocyte maturation, while the recurrent L424H missense mutation drives thymic epithelial transformation via COX-2 upregulation and altered metabolic gene expression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GTF2I encodes TFII-I, a signal-responsive multifunctional transcription factor that defines an alternative, TFIID-dependent transcription initiation pathway by binding directly to initiator (Inr) elements at TATA-less promoters and cooperating with TBP to nucleate distinct preinitiation complexes [#0]. Through its tandem I-repeats and two separable DNA-binding regions, TFII-I recognizes both Inr and E-box elements and acts at basal and upstream regulatory sites of the same gene, often synergizing with partner factors such as USF1 [#2, #10, #25]. It integrates growth-factor and stress signaling at immediate-early and signal-induced promoters—most extensively the c-fos SRE/SIE, which it activates in complex with SRF, Phox1, STAT1/STAT3 and the Ras/MAPK pathway [#3, #7]. Its activity is gated by an unusually dense post-translational network: cytoplasmic-to-nuclear shuttling and transactivation are driven by tyrosine phosphorylation from Btk, Itk, JAK2 and c-Src at residues including Y248, Y357, Y462 and Y611, and by serine phosphorylation from ERK (S627/S633), PKG Iβ (S371/S743) and Cdk1, while Btk and the related repressor MusTRD1/BEN tether or exclude it from the nucleus [#8, #11, #13, #14, #17, #19, #21, #34, #20]. TFII-I transcriptional output is further tuned by HDAC3-mediated repression, which is relieved by PIASxβ and by PIAS4-driven SUMOylation at K221/K240 that weakens HDAC3 binding, and the protein is targeted for p53/ATM-dependent ubiquitin–proteasomal degradation upon genotoxic stress [#15, #16, #38, #32]. Beyond core promoter control, TFII-I links to broad genome organization and signaling: it partners with CTCF to direct promoter-proximal CTCF occupancy and Pol II Ser5 phosphorylation at metabolic genes, mediates Igh enhancer–promoter looping with OCA-B, transduces TGFβ signals via Smad2/3, mediates the ER stress response as the ERSE-binding factor acting with ATF6, drives cyclin D1-dependent S-phase progression, and supports translesion DNA synthesis by bridging PCNA and Pol ζ via Rev7 [#37, #35, #22, #12, #32, #33, #36]. Outside the nucleus, TFII-I suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding [#27]. Haploinsufficiency and dosage imbalance of GTF2I underlie Williams-Beuren syndrome neurocognitive and myelination phenotypes, acting in part through an LSD1-dependent program controlling neural progenitor proliferation and oligodendrocyte maturation, while the recurrent L424H mutation drives thymic epithelial transformation through COX-2 and metabolic gene upregulation [#40, #41, #42, #43].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that TFII-I is not merely an accessory factor but defines a distinct initiation pathway, answering how TATA-less, Inr-containing promoters recruit the basal machinery.\",\n      \"evidence\": \"In vitro transcription reconstitution and preinitiation complex assembly with defined factors\",\n      \"pmids\": [\"8377828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological target promoters in vivo\", \"Structural basis of Inr recognition undefined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed the TFII-I initiation pathway is a regulatable node by demonstrating Myc selectively blocks TFII-I-dependent (not TFIIA-dependent) preinitiation, framing TFII-I as a target of oncogenic control.\",\n      \"evidence\": \"In vitro transcription and PIC formation assays with co-IP\",\n      \"pmids\": [\"8377829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological promoters subject to Myc–TFII-I antagonism not defined\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined TFII-I primary structure (six I-repeats) and dual Inr/E-box DNA-binding capacity, and connected it to upstream factors (USF1, SRF, Phox1) at serum-responsive promoters, explaining how one protein bridges core and enhancer elements.\",\n      \"evidence\": \"cDNA cloning, domain analysis, DNA-binding and reporter assays, biochemical purification (as SPIN)\",\n      \"pmids\": [\"9384587\", \"9334314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of E-box vs Inr selectivity unresolved\", \"No structural model of I-repeats\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Linked TFII-I to receptor signaling by identifying it as a Btk-associated Btk substrate phosphorylated upon BCR crosslinking, opening the kinase-regulated dimension of its biology.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, PH-domain binding mapping, BCR crosslinking\",\n      \"pmids\": [\"9012831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of phosphorylation not yet shown\", \"Which tyrosines phosphorylated not mapped here\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed Inr-specific transcriptional function resides in the N-terminal DNA-binding domain and that tyrosine phosphorylation modulates transactivation without affecting DNA binding, separating recruitment from activation.\",\n      \"evidence\": \"Dominant-negative truncation mutants, in vivo phosphorylation labeling, reporter assays on the TCR Vβ promoter\",\n      \"pmids\": [\"9671454\", \"9837922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab functional dissection\", \"Specific kinases for basal phosphorylation not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the cytoplasm–nucleus shuttling logic: Btk tethers TFII-I in the cytoplasm and BCR signaling dissociates the complex to permit nuclear import, establishing signal-gated subcellular localization.\",\n      \"evidence\": \"Co-IP with Btk domain mutants, subcellular fractionation, BCR crosslinking, reporter assays\",\n      \"pmids\": [\"10373551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor / NLS machinery not defined\", \"Quantitative kinetics of shuttling unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved the structural determinants of oligomerization and DNA binding, showing self-association via the N-terminal leucine zipper and I-repeats aids nuclear translocation and tunes basal vs signal-responsive output.\",\n      \"evidence\": \"Deletion/point mutagenesis, co-IP, fractionation, reporter assays\",\n      \"pmids\": [\"10854432\", \"11113127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of homo/heteromers undefined\", \"Isoform-specific roles incompletely mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected TFII-I to MAPK signaling mechanistically by mapping an ERK docking D-box and ERK phosphorylation sites (S627/S633) required for c-fos activation.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, point mutagenesis, dominant-negative Ras, reporter assays\",\n      \"pmids\": [\"10648599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How serine phosphorylation alters complex assembly not detailed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified TFII-I as the ER stress response element-binding factor (ERSF) acting with ATF6, extending its role to the unfolded protein response at grp78/ERp72 promoters.\",\n      \"evidence\": \"Chromatographic purification, microsequencing, recombinant binding, co-IP with ATF6, knockdown, reporter assays\",\n      \"pmids\": [\"11287625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ER stress signal reaches TFII-I not defined here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapped specific tyrosine kinases (JAK2 at Y248; Btk at Y248/Y357/Y462) to defined residues required for c-fos activity, dissecting which inputs converge on which sites.\",\n      \"evidence\": \"In vitro kinase assays, phosphopeptide mapping, site-directed mutagenesis, dominant-negative JAK2, reporter assays\",\n      \"pmids\": [\"11313464\", \"11373296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial logic of multi-site phosphorylation untested\", \"Spatial/temporal ordering of kinase action unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed the TFII-I-related repressor MusTRD1/BEN antagonizes TFII-I by NLS-dependent nuclear exclusion, identifying a paralog-based regulatory switch.\",\n      \"evidence\": \"Co-expression, localization microscopy, fractionation, NLS mutagenesis, reporter assays\",\n      \"pmids\": [\"11438732\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"In vivo physiological context of antagonism not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the repressive arm of TFII-I regulation by identifying HDAC3 as a bound deacetylase that suppresses transactivation, and PIASxβ/SUMO pathway as a relieving counterforce.\",\n      \"evidence\": \"Immunoaffinity purification, co-IP, GST pulldown, HDAC activity assay, reporter assays\",\n      \"pmids\": [\"12393887\", \"12239342\", \"12193603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration that SUMOylation displaces HDAC3 came later\", \"Genome-wide target promoters of repression not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended kinase regulation to serine/threonine and second-messenger pathways by mapping PKG Iβ phosphorylation at S371/S743 and c-Src phosphorylation at Y248/Y611 driving nuclear translocation.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro kinase assays, mutagenesis, fractionation, stable c-fos reporter cells\",\n      \"pmids\": [\"12082086\", \"11934902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk between Ser and Tyr modifications not integrated\", \"Stoichiometry in vivo unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Clarified that Btk and Src target distinct sites and that Btk tethers TFII-I cytoplasmically by preventing dimerization, showing parallel kinase pathways converge with opposing localization outcomes.\",\n      \"evidence\": \"Domain mapping with deletion/point mutants, co-IP, fractionation\",\n      \"pmids\": [\"14623887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab domain study\", \"Whether dimerization-coupled import is direct mechanism untested structurally\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined TFII-I as a signal-recruited Smad partner in TGFβ/activin signaling controlling developmental and cell-cycle genes, with Ser371/S743 phosphorylation tuning Smad complex formation.\",\n      \"evidence\": \"Co-IP, ChIP, siRNA knockdown, Xenopus antisense, microarray, reporter assays\",\n      \"pmids\": [\"16055724\", \"16055503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs cofactor-mediated DNA contact at Gsc DE not resolved\", \"How phosphorylation alters Smad affinity mechanistically unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated dual Inr/E-box action on endogenous promoters (VEGFR-2) and that c-Src phosphorylation at Y248 couples ER stress to Grp78 induction, unifying its DNA-binding versatility with signal input.\",\n      \"evidence\": \"Gel shift, siRNA, reporter/mutagenesis, ChIP, phospho-specific antibodies, stable knockdown\",\n      \"pmids\": [\"15941713\", \"15664986\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Counter-regulation by TFII-IRD1 mechanism incomplete\", \"Generality across other Inr/E-box genes untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed a non-transcriptional cytoplasmic function: TFII-I suppresses agonist-induced calcium entry by competing with TRPC3 for PLCγ binding, expanding its role beyond the nucleus.\",\n      \"evidence\": \"Calcium entry assays, TRPC3 surface expression, PLCγ SH2/PH-domain interaction mapping\",\n      \"pmids\": [\"17023658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological calcium contexts not established\", \"Reciprocal regulation of nuclear vs cytoplasmic pools unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected TFII-I to immunoglobulin gene regulation in B cells through ARID3a/Bright interaction and tyrosine-dependent heavy-chain transcription.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, reporter assays, mutagenesis\",\n      \"pmids\": [\"16738337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Mechanism of looping not yet shown (later defined via OCA-B)\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established a role in B-cell growth control, with TFII-I restraining c-Myc and modulating NF-κB and CDK inhibitors during signal-dependent growth arrest.\",\n      \"evidence\": \"shRNA silencing, immunoblotting, EMSA for NF-κB subunits, proliferation/apoptosis assays\",\n      \"pmids\": [\"17312101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect transcriptional effects on c-Myc/NF-κB not separated\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed TFII-I cooperates with USF1/USF2 to reactivate latent integrated HIV-1 via the LTR RBEIII element in a TCR/MAPK-dependent manner, extending its enhancer cooperativity to viral transcription.\",\n      \"evidence\": \"EMSA, ChIP, dominant-interfering constructs, TCR crosslinking, MEK inhibition\",\n      \"pmids\": [\"17546494\", \"15767439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution to latency reversal in primary cells not assessed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Implicated TFII-I in dyslexia-associated regulatory variation by showing allele-specific binding within a PARP1/SFPQ complex at the DYX1C1 promoter SNP.\",\n      \"evidence\": \"EMSA, MS identification, protein sequencing, luciferase reporter assays\",\n      \"pmids\": [\"18445785\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link to dyslexia phenotype not established\", \"Functional role of PARP1/SFPQ partnership undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended TFII-I function to transcription elongation by demonstrating Elongin A interaction and Pol II/Elongin A-coupled recruitment at the stress-responsive ATF3 gene genome-wide.\",\n      \"evidence\": \"Biotinylation-tagging ChIP-seq, pulldown, siRNA, Pol II/Elongin A ChIP\",\n      \"pmids\": [\"24875474\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanistic role in elongation vs recruitment not resolved\", \"Single-lab genome-wide dataset\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined TFII-I as a cell-cycle regulator: it activates cyclin D1 to promote S-phase progression, is degraded by p53/ATM-dependent ubiquitination upon genotoxic stress, and is phosphorylated by Cdk1 at the G2/M boundary.\",\n      \"evidence\": \"ChIP, ubiquitination/proteasome assays, stable cells, flow cytometry, mutagenesis, microarray\",\n      \"pmids\": [\"16314517\", \"19182516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating p53-dependent degradation not identified\", \"Direct Cdk1 site on TFII-I not mapped here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified Itk as an additional T-cell tyrosine kinase phosphorylating TFII-I downstream of TCR engagement to potentiate c-fos transcription.\",\n      \"evidence\": \"Co-IP, TCR-crosslinking phosphorylation, kinase-dead/R29C mutants, reporter assays, deletion mapping\",\n      \"pmids\": [\"19701889\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Itk target tyrosines not mapped\", \"Redundancy with Btk in B vs T cells unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided a 3D chromatin mechanism for Igh regulation: promoter-bound TFII-I and enhancer-bound OCA-B mediate enhancer–promoter looping, with OCA-B relieving HDAC3 repression by competing for TFII-I.\",\n      \"evidence\": \"Co-IP, ChIP, chromosome conformation capture, competition binding, reporter assays\",\n      \"pmids\": [\"21549311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of TFII-I-mediated looping at other loci untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a transcription-independent genome-maintenance role: TFII-I bridges PCNA and Pol ζ via Rev7 to support translesion synthesis and DNA damage tolerance.\",\n      \"evidence\": \"Co-IP, TLS functional assays, homodimerization and PCNA-binding mutants\",\n      \"pmids\": [\"24922507\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the PCNA–Pol ζ bridge undefined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed TFII-I in genome organization by showing it directs CTCF promoter-proximal occupancy and Pol II Ser5 phosphorylation at metabolic genes, and refined its PTM logic by defining PIAS4-mediated SUMOylation at K221/K240 that antagonizes HDAC3 binding.\",\n      \"evidence\": \"MS of CTCF interactors, fractionation, ChIP-seq, siRNA; SUMO site mapping, mutagenesis, proliferation/colony assays\",\n      \"pmids\": [\"25646466\", \"25869096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFII-I recruits or stabilizes CTCF mechanistically unclear\", \"Link between SUMO and CTCF arms not integrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed viral exploitation of TFII-I turnover: adenovirus E4-ORF3 first stimulates SUMOylation then drives ubiquitin–proteasomal degradation of TFII-I to derepress a viral promoter.\",\n      \"evidence\": \"Co-IP, ubiquitination/proteasome assays, reporter assays, infection\",\n      \"pmids\": [\"26814176\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase for E4-ORF3-induced degradation not identified\", \"Single virus context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a causal neurodevelopmental mechanism for Williams-Beuren features: neuronal Gtf2i loss reduces oligodendrocyte maturation and myelination, with deficits rescued pharmacologically.\",\n      \"evidence\": \"Neuron-specific conditional knockout, mRNA-seq, EM myelin imaging, electrophysiology, clemastine rescue\",\n      \"pmids\": [\"31011227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving myelination program not pinpointed\", \"Cell-autonomous vs non-autonomous signal to oligodendrocytes unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the dosage-sensitive neurodevelopmental program and effector: GTF2I controls cortical progenitor proliferation and neuron differentiation through LSD1, with LSD1 inhibition rescuing duplication-driven phenotypes.\",\n      \"evidence\": \"Patient-derived cortical organoids, scRNA-seq, proteomics, transgenic mice, LSD1 inhibitor, behavioral assays\",\n      \"pmids\": [\"38019906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical GTF2I–LSD1 mechanism at chromatin not fully mapped\", \"Generalizability across patient genetic backgrounds untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified the oncogenic mechanism of the recurrent L424H mutation in thymic epithelium: mutant TFII-I upregulates COX-2 and glycolytic genes required for transformation and survival under metabolic stress.\",\n      \"evidence\": \"L424H knock-in cells, transcriptomics, transformation assays, COX-2 inhibition, metabolic stress assays\",\n      \"pmids\": [\"32034314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How L424H alters DNA binding/specificity not defined\", \"Single-lab cellular model\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed L424H as an in vivo thymic oncogenic driver, impairing medullary thymic epithelial maturation and driving E2F/MYC-associated thymoma in aged mice.\",\n      \"evidence\": \"Conditional Foxn1-driven knock-in mouse, spatial transcriptomics, IHC, TCR repertoire analysis\",\n      \"pmids\": [\"36049655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link from L424H to E2F/MYC signature not dissected\", \"Long latency mechanism unexplained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TFII-I integrates its dense multi-kinase, SUMO, ubiquitin, and acetylation inputs into a unified code that selects among its many DNA-binding, looping, calcium-suppressing, and DNA-repair functions remains unresolved at the structural and quantitative level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of full-length TFII-I or its I-repeat DNA complexes\", \"Combinatorial PTM logic governing function selection undefined\", \"Mechanism by which L424H rewires specificity toward oncogenic programs unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 7, 12, 22, 25, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 10, 25]},\n      {\"term_id\": \"GO:0140223\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [35, 36, 37]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 9, 19, 20, 32]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 21, 27]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [12, 35, 37]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 7, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 13, 22, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [32, 33]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [12, 24]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [36]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [35, 37]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [40, 41]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 8, 28, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [40, 42, 43]}\n    ],\n    \"complexes\": [\n      \"TFII-I/CTCF chromatin complex\",\n      \"TFII-I/Smad2/3 complex\",\n      \"TFII-I/OCA-B Igh looping complex\",\n      \"TFII-I/PARP1/SFPQ complex\"\n    ],\n    \"partners\": [\n      \"BTK\",\n      \"ERK/MAPK1\",\n      \"JAK2\",\n      \"SRC\",\n      \"HDAC3\",\n      \"ATF6\",\n      \"CTCF\",\n      \"SMAD2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}